var title_f15_60_16320="Drug packet exterior";
var content_f15_60_16320=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51090&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51090&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Drug packet: Exterior view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 426px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photograph shows the hard wax exterior of a drug packet and provides a sense of the packet's size in comparison to average adult fingers.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Hoffman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_60_16320=[""].join("\n");
var outline_f15_60_16320=null;
var title_f15_60_16321="S shape supracondylar fracture";
var content_f15_60_16321=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F60885&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F60885&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    S-shaped supracondylar fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 352px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Clinical appearance. The S-shaped configuration is created by the prominence of the spike of the proximal fragment (A), flexion of the distal fragment (B), and the posterior prominence of the olecranon (C).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kasser JR, Beaty JH. Supracondylar fractures of the distal humerus. In: Rockwood and Wilkins' Fractures in Children, 5th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_60_16321=[""].join("\n");
var outline_f15_60_16321=null;
var title_f15_60_16322="Cauda equina lymphoma";
var content_f15_60_16322=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F58262&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F58262&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cauda equina involvement by non-Hodgkin lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 450px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This T2 sagittal&nbsp;magnetic resonance imaging&nbsp;of the lumbar spine reveals diffuse thickening of nerve roots within the cauda equina (arrows). This finding is suspicious for infiltrative disease, such as lymphoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_60_16322=[""].join("\n");
var outline_f15_60_16322=null;
var title_f15_60_16323="Epinastine: Drug information";
var content_f15_60_16323=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Epinastine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?8/29/8660?source=see_link\">",
"    see \"Epinastine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/31/35314?source=see_link\">",
"    see \"Epinastine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F165353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Elestat&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F165368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, Second Generation",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F165355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Allergic conjunctivitis: Ophthalmic: Instill 1 drop into each eye twice daily. Continue throughout period of exposure, even in the absence of symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F165363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/31/35314?source=see_link\">",
"      see \"Epinastine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Allergic conjunctivitis: Ophthalmic: Children &ge;2 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F165356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15822425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15822426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F165332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as hydrochloride [drops]: 0.05% (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elestat&reg;: 0.05% (5 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F165323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F165335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For ophthalmic use only; avoid touching tip of applicator to eye or other surfaces. Contact lenses should be removed prior to application, may be reinserted after 10 minutes. Do not wear contact lenses if eyes are red.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F165334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of allergic conjunctivitis",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F165366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Burning sensation, folliculosis, hyperemia, pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (1% to 3%), pharyngitis (1% to 3%), rhinitis (1% to 3%), sinusitis (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (10%; defined as cold symptoms and upper respiratory infection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Lacrimation increased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F165338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F165325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bacterial keratitis: Inadvertent contamination of multiple-dose ophthalmic solutions has caused bacterial keratitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact lens wearers: Contains benzalkonium chloride which may be absorbed by contact lenses; remove contact lenses prior to use and wait 10 minutes before reinserting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For topical ophthalmic use only. Not for the treatment of contact lens irritation; do not wear contact lenses if eye is red.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F165329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F165340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F165358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F165339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Elestat Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (5 mL): $169.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Epinastine HCl Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (5 mL): $106.99",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alket (AR);",
"     </li>",
"     <li>",
"      Allerginon (KP);",
"     </li>",
"     <li>",
"      Aresten (KP);",
"     </li>",
"     <li>",
"      Atergit (PE);",
"     </li>",
"     <li>",
"      Flurinol (CN, CO, CR, DO, EC, GT, HN, NI, PA, PE, PY, SV, UY, VE);",
"     </li>",
"     <li>",
"      Furinol (MX);",
"     </li>",
"     <li>",
"      Purivist (CZ, FR);",
"     </li>",
"     <li>",
"      Relestat (AT, BE, CH, CO, DE, DK, ES, FI, GB, GR, HK, IE, IL, IN, IT, KP, NL, NZ, PE, PL, PT, SE, SG, TH, TR, TW);",
"     </li>",
"     <li>",
"      Talerc (BR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F165324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Selective H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor antagonist; inhibits release of histamine from the mast cell; also has affinity for the H",
"     <sub>",
"      2",
"     </sub>",
"     , alpha",
"     <sub>",
"      1",
"     </sub>",
"     , alpha",
"     <sub>",
"      2",
"     </sub>",
"     , and the 5-HT",
"     <sub>",
"      2",
"     </sub>",
"     receptors",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F165337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 3-5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Low systemic absorption following topical application",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Does not cross blood-brain barrier",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 64%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: &lt;10% metabolized",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: I.V.: Urine (55%); feces (30%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8601 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-424AE69C25-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_60_16323=[""].join("\n");
var outline_f15_60_16323=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165353\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165368\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165355\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165363\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165356\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15822425\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15822426\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165332\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165323\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165335\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165334\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165366\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165338\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165325\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299269\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220116\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165329\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165340\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165358\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165339\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539852\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165324\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165337\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8601\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8601|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/29/8660?source=related_link\">",
"      Epinastine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/31/35314?source=related_link\">",
"      Epinastine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_60_16324="Angioplasty PI";
var content_f15_60_16324=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F86000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F86000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 508px\">",
"   <div class=\"ttl\">",
"    Angioplasty",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 488px; height: 630px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    During an angioplasty, your doctor advances a thin plastic tube (called a \"catheter\") with a tiny balloon inside it to your heart. After the catheter reaches the narrowed or blocked artery, the balloon swells up. This opens up the artery and helps restore blood flow to the heart.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_60_16324=[""].join("\n");
var outline_f15_60_16324=null;
var title_f15_60_16325="AGEP detail 2";
var content_f15_60_16325=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86912&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86912&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Acute generalized exanthematous pustulosis (AGEP)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 371px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_60_16325=[""].join("\n");
var outline_f15_60_16325=null;
var title_f15_60_16326="Histopathology of cardiomyocytes with cytoplasmic vacuoles";
var content_f15_60_16326=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F87853&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F87853&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Histopathology of cardiomyocytes with cytoplasmic vacuoles in hydroxychloroquine cardiomyopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 377px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The histopathology using H and E stain, with 300x magnification, reveals cardiomyocytes with abundant cytoplasmic vacuoles.",
"    <div class=\"footnotes\">",
"     H and E: hematoxylin and eosin.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Aleksandr Perepletchikov, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_60_16326=[""].join("\n");
var outline_f15_60_16326=null;
var title_f15_60_16327="Capillaria philippinensis life cycle";
var content_f15_60_16327=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F65145&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F65145&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 477px\">",
"   <div class=\"ttl\">",
"    Capillaria philippinensis life cycle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 457px; height: 597px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Typically, unembryonated eggs are passed in the human stool",
"    <strong>",
"     (1)",
"    </strong>",
"    and become embryonated in the external environment",
"    <strong>",
"     (2)",
"    </strong>",
"    ; after ingestion by freshwater fish, larvae hatch, penetrate the intestine, and migrate to the tissues",
"    <strong>",
"     (3)",
"    </strong>",
"    . Ingestion of raw or undercooked fish results in infection of the human host",
"    <strong>",
"     (4)",
"    </strong>",
"    . The adults of",
"    <em>",
"     Capillaria philippinensis",
"    </em>",
"    (males: 2.3 to 3.2 mm; females: 2.5 to 4.3 mm) reside in the human small intestine, where they burrow in the mucosa",
"    <strong>",
"     (5)",
"    </strong>",
"    . The females deposit unembryonated eggs. Some of these become embryonated in the intestine, and release larvae that can cause autoinfection. This leads to hyperinfection (a massive number of adult worms)",
"    <strong>",
"     (6)",
"    </strong>",
"    .",
"    <em>",
"     Capillaria philippinesis",
"    </em>",
"    is currently considered a parasite of fish eating birds, which seem to be the natural definitive host",
"    <strong>",
"     (7)",
"    </strong>",
"    .",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Capillariasis. Available at:",
"     <a href=\"file://www.dpd.cdc.gov/dpdx/html/capillariasis.htm\" target=\"_blank\">",
"      file://www.dpd.cdc.gov/dpdx/html/capillariasis.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_60_16327=[""].join("\n");
var outline_f15_60_16327=null;
var title_f15_60_16328="Antiretroviral medications in pregnancy: Non-nucleoside reverse transcriptase inhibitors";
var content_f15_60_16328=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Antiretroviral medications in pregnancy: Non-nucleoside reverse transcriptase inhibitors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/60/16328/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/60/16328/contributors\">",
"     Elaine J Abrams, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/60/16328/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/60/16328/contributors\">",
"     Lynne M Mofenson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/60/16328/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/60/16328/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/60/16328/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decisions regarding antiretroviral therapy in the pregnant female are complex and need to take into consideration various factors, such as possible changes in pharmacokinetics due to physiologic changes, potential toxicities that may be magnified during pregnancy, and potential toxicity to the fetus",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    newborn.",
"   </p>",
"   <p>",
"    The non-nucleoside reverse transcriptase inhibitors (NNRTIs) are a class of antiretroviral agents with potent anti-HIV activity. One of these agents,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    , plays an important role in the prevention of perinatal HIV transmission. The pharmacology, mechanism of action, and side effects of nevirapine are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37162?source=see_link\">",
"     \"Pharmacology of non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will address data regarding the safety of the NNRTIs in pregnancy. Information about the use of other classes of drugs during pregnancy is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42841?source=see_link\">",
"     \"Antiretroviral medications in pregnancy: Nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/24/18825?source=see_link\">",
"     \"Antiretroviral medications in pregnancy: Protease inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24037?source=see_link\">",
"     \"Antiretroviral medications in pregnancy: Entry and integrase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical outcomes in women who are treated with antiretroviral therapy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=see_link\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy should not preclude the use of an optimal antiretroviral therapy regimen for the control of HIV disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16328/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. An additional goal of HIV therapy is to decrease the risk of perinatal transmission of HIV infection. Thus, all pregnant women, regardless of immunologic or virologic parameters, are treated with antiretroviral therapy to prevent perinatal transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16328/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Discussion of ART selection and treatment considerations in the pregnant HIV-infected female is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=see_link\">",
"     \"Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=see_link\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinicians are advised to report instances of prenatal exposure to antiretroviral therapy drugs to the Antiretroviral Pregnancy Registry at",
"    <a class=\"external\" href=\"file://www.apregistry.com/\">",
"     www.APRegistry.com",
"    </a>",
"    ; Telephone 1-800-258-4263. The registry is a collaborative project of pharmaceutical manufacturers with an advisory committee of obstetric and pediatric practitioners.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     AVAILABLE AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nonnucleoside reverse transcriptase inhibitor (NNRTI) group of agents includes the following:",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     Efavirenz",
"    </a>",
"    &nbsp; &nbsp; &nbsp;EFV; Sustiva",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     Nevirapine",
"    </a>",
"    &nbsp; &nbsp;NVP; Viramune",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/10/27816?source=see_link\">",
"     Delavirdine",
"    </a>",
"    &nbsp; DLV; Rescriptor",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     Etravirine",
"    </a>",
"    &nbsp; &nbsp; ETV; Intelence",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/10/27816?source=see_link\">",
"     Delavirdine",
"    </a>",
"    (Rescriptor) is very rarely used as an ARV agent because it is the least potent of the NNRTIs, has a high pill burden (six per day), wide interpatient variability of plasma concentrations, and requires three times daily dosing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37162?source=see_link\">",
"     \"Pharmacology of non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLASS EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are significant differences among agents in this class in terms of potential adverse effects, which play an important role in drug selection. Specifically, due to concerns regarding potential teratogenicity,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    should NOT be administered during the first trimester of pregnancy. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Efavirenz'",
"    </a>",
"    below.) Use after the first trimester can be considered if this is the best choice for an individual woman; if the drug is continued postpartum, adequate contraception should be assured.",
"   </p>",
"   <p>",
"    In contrast,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    has been studied extensively in pregnancy and is not associated with teratogenicity. However, nevirapine is associated with a hypersensitivity syndrome that consists of fever, rash, and hepatotoxicity; not all components are present in every case. The risk of hypersensitivity is higher in patients with a relatively preserved CD4 cell count. Consequently, NVP is not recommended in women with CD4 counts &gt;250",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    unless the benefit clearly outweighs the risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37162?source=see_link\">",
"     \"Pharmacology of non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     Nevirapine",
"    </a>",
"    should be discontinued in any patient who presents with rash",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fever; liver function tests should be checked immediately. Rash can also occur with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/10/27816?source=see_link\">",
"     delavirdine",
"    </a>",
"    . However, delavirdine is uncommonly used due to lower potency and frequency of dosing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37162?source=see_link&amp;anchor=H22#H22\">",
"     \"Pharmacology of non-nucleoside reverse transcriptase inhibitors\", section on 'Nevirapine (Viramune)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another major disadvantage for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    is that a single resistance mutation (eg, K103) can lead to complete loss of antiviral activity; this property is sometimes referred to as a \"low genetic barrier\" to resistance.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     Etravirine",
"    </a>",
"    (TMC 125; Intelence) is a second generation NNRTI that may be effective in patients with NNRTI resistance mutations. However, this agent has not been studied in pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34218?source=see_link\">",
"     \"Primer on interpretation of HIV drug resistance testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37162?source=see_link\">",
"     \"Pharmacology of non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EFAVIRENZ",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     Efavirenz",
"    </a>",
"    (Sustiva) is US Food and Drug Administration (FDA) pregnancy category D and should not be used during the first trimester of pregnancy (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Carcinogenicity animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In long-term animal carcinogenicity studies in mice at systemic drug exposures approximately 1.7-fold higher than observed with standard dosing in humans, no increases in tumor incidence above background were observed in male mice; however, increases in hepatocellular adenomas and carcinomas and pulmonary",
"    <span class=\"nowrap\">",
"     alveolar/bronchiolar",
"    </span>",
"    adenomas above background were found in female mice. In rats administered systemic drug exposures lower than that in humans receiving therapeutic doses, no increase in tumor incidence above background was observed in male or female rats.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Reproduction/fertility animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;No effect on reproduction or fertility in rodents has been seen. An increase in fetal resorptions has been observed in rats at doses comparable to or lower than those with human therapeutic exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Teratogenicity/developmental toxicity animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant central nervous system malformations were observed in 3 of 20 infants born to pregnant cynomolgus monkeys receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    from gestational day 20 to 150 in doses comparable to systemic human therapeutic exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16328/abstract/3\">",
"     3",
"    </a>",
"    ]. The malformations included anencephaly and unilateral anophthalmia in one; microphthalmia in another; and cleft palate in the third.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Placental passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     Efavirenz",
"    </a>",
"    crosses the placenta in rats, rabbits, and primates, producing cord blood concentrations similar to the maternal concentration. In a small study of 13 women who received efavirenz during the last trimester of pregnancy and for six months after delivery, mean neonatal plasma efavirenz concentrations were 13.1 percent of maternal plasma levels [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16328/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Breast milk passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     Efavirenz",
"    </a>",
"    passes into breast milk; in a small study of 13 women between six weeks and six months postpartum, efavirenz passed into breast milk with mean breast milk to maternal plasma concentration of 0.54 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16328/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Human studies in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     Efavirenz",
"    </a>",
"    is classified as FDA Pregnancy Category D (positive evidence of human fetal risk that is based on adverse reaction data from investigational or marketing experiences, but the potential benefits from use of the drug among pregnant women may be acceptable despite potential risks).",
"   </p>",
"   <p>",
"    In prospective data from the Antiretroviral Pregnancy Registry, the overall risk of birth defects with first trimester",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    exposure was similar to that in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16328/abstract/2\">",
"     2",
"    </a>",
"    ]. However, it was concerning that the defects reported included one neural tube defect (meningomyelocele) and one report of anophthalmia with severe facial clefts and amniotic banding [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16328/abstract/5\">",
"     5",
"    </a>",
"    ], because of the consistency with defects found in the primate studies above. A meta-analysis of 19 prospective studies evaluating 1437 women with first trimester efavirenz exposure, including the Antiretroviral Pregnancy Registry, did not find an increased relative risk of overall birth defects comparing infants born to women receiving efavirenz-based versus non-efavirenz&ndash;based regimens (relative risk 0.85, 95% CI 0.6-1.2) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16328/abstract/6\">",
"     6",
"    </a>",
"    ]. The meningomyelocele reported in the Antiretroviral Pregnancy Registry was the only neural tube defect identified across those studies, giving an incidence of 0.07 percent (95% CI 0.02-0.39 percent).",
"   </p>",
"   <p>",
"    Although studies from two large pediatric AIDS cohorts (PACTG 219 and P1025) have reported an increased risk of birth defects with first trimester",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    exposure compared with exposure to other antiretroviral drugs, no specific pattern of birth defects was observed, and there was overlap in reported defects between the two papers [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16328/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Because the defect of concern (neural tube defect) has a low prevalence in the general US population (0.02 to 0.2 percent), several thousand first trimester exposures are required to rule out an increase in incidence [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16328/abstract/9\">",
"     9",
"    </a>",
"    ]. The currently available data cannot rule out a two- or threefold increased incidence of a rare outcome such as neural tube defects with first trimester efavirenz. However, there are sufficient data to suggest that there is not a large, 10-fold or higher increase in risk.",
"   </p>",
"   <p>",
"    The risk of neural tube defects is restricted to the first five weeks of pregnancy, as the neural tube closes at approximately 28 days post-fertilization [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16328/abstract/10\">",
"     10",
"    </a>",
"    ]. Thus,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    is not recommended for use in women planning to become pregnant or in women of childbearing potential not using effective contraception, and it should not be initiated during the first trimester of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16328/abstract/1\">",
"     1",
"    </a>",
"    ]. Given that pregnancy is rarely recognized prior to four to six weeks of gestation and unnecessary antiretroviral drug changes during pregnancy may be associated with loss of viral control and increased risk of perinatal transmission, women who become pregnant while receiving efavirenz should continue their regimen provided there is virologic suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16328/abstract/11\">",
"     11",
"    </a>",
"    ]. In such situations, additional fetal monitoring (eg, second trimester ultrasound) should be considered to evaluate fetal anatomy",
"   </p>",
"   <p>",
"    Selection of ART during pregnancy is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=see_link&amp;anchor=H328768#H328768\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\", section on 'Guide to drug selection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=see_link&amp;anchor=H2033166#H2033166\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\", section on 'Efavirenz'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pharmacokinetics of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    during pregnancy do not appear to be significantly different from that in nonpregnant adults. In 25 pregnant women taking efavirenz as part of combination antiretroviral therapy, the clearance of efavirenz was higher and the concentration at 24 hours was lower during the third trimester than several weeks postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16328/abstract/12\">",
"     12",
"    </a>",
"    ]. However, the area under the curve remained similar at both time points and was comparable to that reported in nonpregnant adults. Thus, no dose modification of efavirenz is required during the third trimester of pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     NEVIRAPINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    is not associated with teratogenicity, the use of this drug has been associated with a hypersensitivity syndrome that consists of fever, rash, and hepatotoxicity. Nevirapine (Viramune) is FDA pregnancy category C (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Carcinogenicity animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatocellular adenomas and carcinomas were increased in mice and rats.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Reproduction/fertility animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence of impaired fertility was seen in female rats at doses providing systemic exposure comparable to human therapeutic exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Teratogenicity/developmental toxicity animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Teratogenic effects have not been observed in reproductive studies with rats and rabbits. In the Antiretroviral Pregnancy Registry, no increase in the risk of birth defects has been observed with first trimester exposure to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16328/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Placental passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     Nevirapine",
"    </a>",
"    crosses the placenta and achieves neonatal blood concentrations equivalent to those in the mother (cord-to-maternal blood ratio approximately 1.0) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16328/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Breast milk passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     Nevirapine",
"    </a>",
"    is excreted into human breast milk. In studies in breastfeeding women in Africa, the median breast milk concentration of NVP was lower than that in maternal serum, ranging between 67 to 90 percent of maternal serum levels [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16328/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Human studies in pregnancy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Pharmacokinetic data",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacokinetic data on chronic antenatal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    dosing in pregnant women during the third trimester has demonstrated that pharmacokinetic parameters in the pregnant woman are similar to those in non-pregnant adults [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16328/abstract/17\">",
"     17",
"    </a>",
"    ]. Serum nevirapine elimination in the infants was accelerated compared to newborns whose mothers received only a single intrapartum dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;In non-pregnant individuals severe skin rash (including Stevens Johnson syndrome) and life-threatening hepatotoxicity have been reported. These serious adverse events are more common in women than men and usually occur within the first 18 weeks of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16328/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. The risk of these events increases in women with higher CD4 cell counts; in a summary analysis of data from 17 trials, women with CD4 counts &gt;250",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    were 9.8 times more likely to experience early serious, and potentially life-threatening, nevirapine-associated hepatotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16328/abstract/18\">",
"     18",
"    </a>",
"    ]. Severe nevirapine-associated skin rash, hepatotoxicity and liver failure have also been reported in pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16328/abstract/20-25\">",
"     20-25",
"    </a>",
"    ]. This topic is discussed in detail elsewhere (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37162?source=see_link\">",
"     \"Pharmacology of non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There are conflicting observational data about whether",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    use is associated with an increased risk of hepatotoxicity in pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16328/abstract/23,25-28\">",
"     23,25-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In pregnant women with a CD4 cell count &gt;250",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    should be used as a component of ART only if the benefit clearly outweighs the risk [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16328/abstract/1\">",
"     1",
"    </a>",
"    ]. In contrast, a pregnant woman who enters care on a nevirapine-containing regimen and is tolerating ART well may continue her initial regimen, regardless of CD4 cell count. Some data suggest that the risk of hepatotoxicity declines with HIV RNA suppression. This topic is discussed in detail elsewhere (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37162?source=see_link\">",
"     \"Pharmacology of non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=see_link\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In contrast to persons receiving chronic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    , these reactions have",
"    <strong>",
"     not",
"    </strong>",
"    been reported in women or infants receiving two-dose",
"    <span class=\"nowrap\">",
"     intrapartum/newborn",
"    </span>",
"    nevirapine (the HIVNET 012 regimen) for prevention of perinatal transmission.",
"   </p>",
"   <p>",
"    Decisions about the selection of ART in women of childbearing potential and patient monitoring on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=see_link\">",
"     \"Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=see_link\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Drug resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     Nevirapine",
"    </a>",
"    -resistant virus has been observed in women who have received a single dose of intrapartum nevirapine [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16328/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. Nevirapine resistance is rare in a woman who is receiving nevirapine as part of a fully suppressive combination therapy regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     DELAVIRDINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/10/27816?source=see_link\">",
"     Delavirdine",
"    </a>",
"    (Rescriptor) is classified as FDA pregnancy category C (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ). In pregnant women, delavirdine is not recommended due to a paucity of clinical data during pregnancy and concerns regarding teratogenicity in animals [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16328/abstract/1\">",
"     1",
"    </a>",
"    ]. Delavirdine is also uncommonly used in the general population of HIV-infected patients due to its lower potency compared to other agents and due to the need for three times daily dosing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Carcinogenicity animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In mice,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/10/27816?source=see_link\">",
"     delavirdine",
"    </a>",
"    was associated with an increase in hepatocellular adenomas and carcinomas in both males and females and urinary bladder tumors in males; in rats, delavirdine was non-carcinogenic at all doses studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Reproduction/fertility animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/10/27816?source=see_link\">",
"     Delavirdine",
"    </a>",
"    does not impair fertility in rodents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Teratogenicity/developmental toxicity animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/10/27816?source=see_link\">",
"     Delavirdine",
"    </a>",
"    was associated with the development of ventricular septal defects in rats. Primate teratogenicity studies have not been conducted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Placental passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unknown",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Breast milk passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/10/27816?source=see_link\">",
"     Delavirdine",
"    </a>",
"    is excreted in the milk of lactating rats; it is unknown if excreted in human breast milk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Human studies in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/10/27816?source=see_link\">",
"     Delavirdine",
"    </a>",
"    has not been evaluated in infected pregnant women.",
"   </p>",
"   <p>",
"    In premarketing clinical studies, the outcomes of seven unplanned pregnancies while taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/10/27816?source=see_link\">",
"     delavirdine",
"    </a>",
"    included ectopic pregnancy (n = 3); ventricular septal defect (n = 1) and three healthy live births.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     ETRAVIRINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     Etravirine",
"    </a>",
"    is in FDA Pregnancy Category B, indicating that there are not well-controlled studies of this drug in humans, but that animal studies have not shown any teratogenic effects. According to the FDA, etravirine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Any patient who receives etravirine while pregnant should be registered with the Antiretroviral Pregnancy Registry by calling 1-800-258-4263. In general, etravirine is administered as part of combination therapy in patients with multi-drug resistance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37162?source=see_link\">",
"     \"Pharmacology of non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Carcinogenicity animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro carcinogenicity studies of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    have been negative; long-term carcinogenicity studies of etravirine in rodents are ongoing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Reproduction/fertility animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;No effect on fertility and early embryonic development were observed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    systemic drug exposures that were approximately the same as with the recommended human dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Teratogenicity/developmental toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Animal reproduction studies in rats and rabbits, at systemic exposures equivalent to those at recommended human dose, revealed no evidence of fetal harm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Placental and breast milk passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data on whether",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    crosses the placenta or is excreted in breast milk in humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Human studies in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited clinical data regarding the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    in pregnant women. In one study of five women who received etravirine during the first or third trimesters up until delivery, preliminary data suggest that the pharmacokinetics of etravirine in pregnant women may be similar to nonpregnant women; no neonatal toxicity was noted in this small case series [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16328/abstract/32\">",
"     32",
"    </a>",
"    ]. Further evaluation of etravirine during pregnancy is ongoing [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16328/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here is the patient education article that is relevant to this topic. We encourage you to print or e-mail this topic to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/29/7635?source=see_link\">",
"       \"Patient information: HIV and pregnancy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H518749\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decisions regarding antiretroviral therapy in the pregnant female are complex and need to take into consideration various factors, such as possible changes in pharmacokinetics due to physiologic changes, potential toxicities that may be magnified during pregnancy, and potential toxicity to the fetus",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      newborn. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pregnancy should not preclude the use of an optimal antiretroviral therapy regimen for the control of HIV disease. An additional goal of HIV therapy is to decrease the risk of perinatal transmission of HIV infection. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Due to concerns regarding potential teratogenicity,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      should not be initiated during the first trimester of pregnancy and should be avoided in women of child-bearing age who are not using contraception. However, women who become pregnant while taking an efavirenz-containing regimen can continue it provided they have achieved viral suppression. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Efavirenz'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      is not associated with teratogenicity, the use of this drug has been associated with a hypersensitivity syndrome that consists of fever, rash, and hepatotoxicity. Since the risk of hypersensitivity is higher in patients with a relatively preserved CD4 cell count, nevirapine is not recommended in women with CD4 counts &gt;250",
"      <span class=\"nowrap\">",
"       cells/mm3",
"      </span>",
"      unless the benefit clearly outweighs the risk. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Nevirapine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are few data regarding the safety of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"       etravirine",
"      </a>",
"      use during pregnancy. Etravirine, which is usually administered in patients with multi-drug resistance, should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Etravirine'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Public Health Service Task Force Recommendations for use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. September 14, 2011. www.AIDSInfo.nih.gov (Accessed on March 16, 2012).",
"    </li>",
"    <li>",
"     Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry international interim report for 1 Jan 1989 - 31 July 2011. Wilmington, NC: Registry Coordinating Center; 2007. file://www.APRegistry.com (Accessed on March 22, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16328/abstract/3\">",
"      Nightingale SL. From the Food and Drug Administration. JAMA 1998; 280:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16328/abstract/4\">",
"      Schneider S, Peltier A, Gras A, et al. Efavirenz in human breast milk, mothers', and newborns' plasma. J Acquir Immune Defic Syndr 2008; 48:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16328/abstract/5\">",
"      Shanske AL. Bilateral oblique facial clefts and extremity anomaly in an infant after intrauterine efavirenz exposure and review of its teratogenic risk. AIDS 2012; 26:1775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16328/abstract/6\">",
"      Ford N, Calmy A, Mofenson L. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS 2011; 25:2301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16328/abstract/7\">",
"      Brogly SB, Abzug MJ, Watts DH, et al. Birth defects among children born to human immunodeficiency virus-infected women: pediatric AIDS clinical trials protocols 219 and 219C. Pediatr Infect Dis J 2010; 29:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16328/abstract/8\">",
"      Knapp KM, Brogly SB, Muenz DG, et al. Prevalence of congenital anomalies in infants with in utero exposure to antiretrovirals. Pediatr Infect Dis J 2012; 31:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16328/abstract/9\">",
"      Watts DH. Teratogenicity risk of antiretroviral therapy in pregnancy. Curr HIV/AIDS Rep 2007; 4:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16328/abstract/10\">",
"      Sadler TW. Embryology of neural tube development. Am J Med Genet C Semin Med Genet 2005; 135C:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16328/abstract/11\">",
"      Floridia M, Ravizza M, Pinnetti C, et al. Treatment change in pregnancy is a significant risk factor for detectable HIV-1 RNA in plasma at end of pregnancy. HIV Clin Trials 2010; 11:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16328/abstract/12\">",
"      Cressey TR, Stek A, Capparelli E, et al. Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum. J Acquir Immune Defic Syndr 2012; 59:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16328/abstract/13\">",
"      Mirochnick M, Fenton T, Gagnier P, et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis 1998; 178:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16328/abstract/14\">",
"      Musoke P, Guay LA, Bagenda D, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS 1999; 13:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16328/abstract/15\">",
"      Shapiro RL, Holland DT, Capparelli E, et al. Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment. J Infect Dis 2005; 192:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16328/abstract/16\">",
"      Colebunders R, Hodossy B, Burger D, et al. The effect of highly active antiretroviral treatment on viral load and antiretroviral drug levels in breast milk. AIDS 2005; 19:1912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16328/abstract/17\">",
"      Mirochnick M, Siminski S, Fenton T, et al. Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure. Pediatr Infect Dis J 2001; 20:803.",
"     </a>",
"    </li>",
"    <li>",
"     Stern JO, Love JT, Robinson PA, et al. Hepatic safety of nevirapine: Results of the Boehringer Ingelheim Viramune Hepatic Safety Project. 14th International Conference on AIDS. Barcelona, Spain. July 7-12, 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16328/abstract/19\">",
"      Bersoff-Matcha SJ, Miller WC, Aberg JA, et al. Sex differences in nevirapine rash. Clin Infect Dis 2001; 32:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16328/abstract/20\">",
"      Knudtson E, Para M, Boswell H, Fan-Havard P. Drug rash with eosinophilia and systemic symptoms syndrome and renal toxicity with a nevirapine-containing regimen in a pregnant patient with human immunodeficiency virus. Obstet Gynecol 2003; 101:1094.",
"     </a>",
"    </li>",
"    <li>",
"     Lyons F, Hopkins S, McGeary A, et al. Nevirapine tolerability in HIV infected women in pregnancy - A word of caution. 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France. July 13-16, 2003 (late breaker).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16328/abstract/22\">",
"      Hitti J, Frenkel LM, Stek AM, et al. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J Acquir Immune Defic Syndr 2004; 36:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16328/abstract/23\">",
"      Timmermans S, Tempelman C, Godfried MH, et al. Nelfinavir and nevirapine side effects during pregnancy. AIDS 2005; 19:795.",
"     </a>",
"    </li>",
"    <li>",
"     Langlet P, Guillaume MP, Devriendt J, et al. Fatal liver failure associated with nevirapine in a pregnant HIV patient: the first reported case. Gastroenterol 2000;118 (suppl 2):Abs 6623 (101st Annual Meeting of the American Gastroenterological Association, San Diego, May 21-24, 2000).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16328/abstract/25\">",
"      Joy S, Poi M, Hughes L, et al. Third-trimester maternal toxicity with nevirapine use in pregnancy. Obstet Gynecol 2005; 106:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16328/abstract/26\">",
"      Ouyang DW, Brogly SB, Lu M, et al. Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretrovirals. AIDS 2010; 24:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16328/abstract/27\">",
"      Aaron E, Kempf MC, Criniti S, et al. Adverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medication. PLoS One 2010; 5:e12617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16328/abstract/28\">",
"      Peters PJ, Stringer J, McConnell MS, et al. Nevirapine-associated hepatotoxicity was not predicted by CD4 count &ge;250 cells/&mu;L among women in Zambia, Thailand and Kenya. HIV Med 2010; 11:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16328/abstract/29\">",
"      Eshleman SH, Guay LA, Mwatha A, et al. Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012). J Acquir Immune Defic Syndr 2004; 35:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16328/abstract/30\">",
"      Eshleman SH, Hoover DR, Chen S, et al. Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis 2005; 192:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16328/abstract/31\">",
"      Cunningham CK, Chaix ML, Rekacewicz C, et al. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. J Infect Dis 2002; 186:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16328/abstract/32\">",
"      Izurieta P, Kakuda TN, Feys C, Witek J. Safety and pharmacokinetics of etravirine in pregnant HIV-1-infected women. HIV Med 2011; 12:257.",
"     </a>",
"    </li>",
"    <li>",
"     clinicaltrials.gov. Trial #NCT00855335.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3783 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-AB43D6AFE1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_60_16328=[""].join("\n");
var outline_f15_60_16328=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H518749\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      AVAILABLE AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLASS EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EFAVIRENZ",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Carcinogenicity animal studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Reproduction/fertility animal studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Teratogenicity/developmental toxicity animal studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Placental passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Breast milk passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Human studies in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      NEVIRAPINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Carcinogenicity animal studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Reproduction/fertility animal studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Teratogenicity/developmental toxicity animal studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Placental passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Breast milk passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Human studies in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Pharmacokinetic data",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Drug resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      DELAVIRDINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Carcinogenicity animal studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Reproduction/fertility animal studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Teratogenicity/developmental toxicity animal studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Placental passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Breast milk passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Human studies in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      ETRAVIRINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Carcinogenicity animal studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Reproduction/fertility animal studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Teratogenicity/developmental toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Placental and breast milk passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Human studies in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H518749\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3783\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3783|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\" title=\"table 1\">",
"      Drug ratings in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24037?source=related_link\">",
"      Antiretroviral medications in pregnancy: Entry and integrase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42841?source=related_link\">",
"      Antiretroviral medications in pregnancy: Nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/24/18825?source=related_link\">",
"      Antiretroviral medications in pregnancy: Protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/29/7635?source=related_link\">",
"      Patient information: HIV and pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37162?source=related_link\">",
"      Pharmacology of non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=related_link\">",
"      Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34218?source=related_link\">",
"      Primer on interpretation of HIV drug resistance testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=related_link\">",
"      Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_60_16329="Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction";
var content_f15_60_16329=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/60/16329/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/60/16329/contributors\">",
"     Judith S Hochman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/60/16329/contributors\">",
"     Venu Menon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/60/16329/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/60/16329/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/60/16329/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/60/16329/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/60/16329/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiogenic shock is a clinical condition of inadequate tissue (end-organ) perfusion due to the inability of the heart to pump an adequate amount of blood. The reduction in tissue perfusion results in decreased oxygen and nutrient delivery to the tissues and, if prolonged, potentially end-organ damage and multi-system failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=see_link&amp;anchor=H1#H1\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\", section on 'Introduction'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    All forms of shock, including hypovolemic and distributive, are characterized by relatively low blood pressure and manifestations of end-organ hypoperfusion, such as poor mentation or low urine output. Patients with cardiogenic shock have a low cardiac index (&lt;2.2",
"    <span class=\"nowrap\">",
"     L/min/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    elevated filling pressures of the left, right, or both ventricles, and a decreased mixed venous oxygen saturation (",
"    <a class=\"graphic graphic_table graphicRef73000 \" href=\"UTD.htm?17/34/17963\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16329/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The systemic vascular resistance is often high, but it may be in the normal or low range.",
"   </p>",
"   <p>",
"    Acute myocardial infarction (MI) is the most common cause of cardiogenic shock and is defined as a clinical event consequent to the death of cardiac myocytes (myocardial necrosis) that is caused by ischemia (as opposed to other etiologies such as myocarditis or trauma). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=see_link&amp;anchor=H4#H4\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\", section on 'Acute MI'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cardiogenic shock is the leading cause of death in patients with acute MI, with hospital mortality rates approaching 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16329/abstract/4\">",
"     4",
"    </a>",
"    ]. Short-term prognosis is directly related to the severity of the hemodynamic disorder. The clinical manifestations and diagnosis of cardiogenic shock in acute (MI) will be reviewed here. The prognosis and treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=see_link\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An overview of the types of shock in adults and the diagnostic approach to such patients are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=see_link\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Failure of the left or right ventricle (due to myocardial muscle dysfunction) to pump an adequate amount of blood is the primary cause of cardiogenic shock in acute MI (",
"    <a class=\"graphic graphic_figure graphicRef65867 \" href=\"UTD.htm?3/33/3603\">",
"     figure 1",
"    </a>",
"    ). Hypotension, tissue hypoperfusion, and pulmonary congestion or systemic venous congestion result.",
"   </p>",
"   <p>",
"    Systemic hypotension, which is present in most patients with cardiogenic shock, is defined as a persistent systolic blood pressure below 80 to 90 mmHg or a mean blood pressure 30 mmHg lower than the patient's baseline level. In cardiogenic shock, hypotension results from a decrease in stroke volume and a severe reduction in the cardiac index (&lt;1.8",
"    <span class=\"nowrap\">",
"     L/",
"    </span>",
"    min per m",
"    <sup>",
"     2",
"    </sup>",
"    without support or &lt;2.0 to 2.2",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    per m",
"    <sup>",
"     2",
"    </sup>",
"    with support).",
"   </p>",
"   <p>",
"    The fall in blood pressure may in part be moderated by a marked elevation in systemic vascular resistance (SVR), a response that is mediated by increased release of endogenous vasopressors such as norepinephrine and angiotensin II. However, the combination of a low cardiac output and elevated SVR may result in a marked reduction in tissue perfusion.",
"   </p>",
"   <p>",
"    The associated decrease in coronary perfusion pressure can lead to a vicious cycle of ischemia, further myocardial dysfunction, and a downward spiral with progressive end-organ hypoperfusion and ultimately death [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16329/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypotension and elevation of SVR occur in the presence of an elevated pulmonary capillary wedge pressure if left ventricular dysfunction is the primary cardiac disorder. (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23076?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathophysiology of heart failure: Left ventricular pressure-volume relationships\", section on 'Normal left ventricular pressure-volume relationship'",
"    </a>",
"    ). Elevation of the right ventricular (RV) filling pressure occurs when isolated RV shock is present, such as might occur with a large right ventricular infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16329/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Etiology'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/57/922?source=see_link\">",
"     \"Right ventricular myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute myocardial infarction, due to acute occlusion of one or more coronary arteries, is the most common clinical entity leading to cardiogenic shock. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Etiology'",
"    </a>",
"    below.) In this setting myocardial ischemia or infarction leads to a fall in the stroke volume (of either the left or right ventricle or both) and cardiac output and, as mentioned above, often a compensatory increase in the systemic vascular resistance.",
"   </p>",
"   <p>",
"    However, not all patients fall into this hemodynamic profile. In the SHOCK trial of patients with confirmed cardiogenic shock developing within 36 hours of an acute MI, the mean left ventricular ejection fraction on echocardiography was unexpectedly high at 31 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16329/abstract/8\">",
"     8",
"    </a>",
"    ]. Furthermore, calculated systemic vascular resistance varied widely and on average was not elevated despite vasopressor use [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16329/abstract/2\">",
"     2",
"    </a>",
"    ]. Thus, in some patients, post-MI shock is accompanied by relative vasodilation rather than vasoconstriction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=see_link&amp;anchor=H6#H6\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\", section on 'Distributive'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    The most likely explanation for vasodilation in the setting of cardiogenic shock is the presence of a systemic inflammatory state similar to that seen with sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16329/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24744?source=see_link\">",
"     \"Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis\"",
"    </a>",
"    ). In the SHOCK trial, 54 of the 302 patients (18 percent) had fever",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    leukocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16329/abstract/3\">",
"     3",
"    </a>",
"    ]. The systemic inflammation was diagnosed two to four days after the onset of shock and these patients had a relatively lower systemic vascular resistance. Among the 54 patients, 40 were subsequently considered to be potentially infected as evidenced by a positive culture; 14 were culture negative. The lower the initial systemic vascular resistance, the greater the likelihood of developing culture positive systemic inflammation. The latter observation suggests that inappropriate vasodilation may play an important role in both the pathogenesis and persistence of shock and in the likelihood of infection.",
"   </p>",
"   <p>",
"    The acute inflammatory response in myocardial infarction is associated with elevated serum cytokine concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16329/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Cytokine activation leads to induction of nitric oxide (NO) synthase and increased levels of NO, which can cause inappropriate vasodilation with reduced systemic and coronary perfusion pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16329/abstract/2,11\">",
"     2,11",
"    </a>",
"    ]. This sequence may be similar to that seen in septic shock, which is also characterized by systemic vasodilation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=see_link&amp;anchor=H6#H6\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\", section on 'Distributive'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H607023030\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of cardiogenic shock after MI was constant in the 1970s and 1980s and complicated approximately 5 to 9 percent of acute ST-elevation myocardial infarction (STEMI) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16329/abstract/1,12-15\">",
"     1,12-15",
"    </a>",
"    ]. More recent data (between the late 1990s and 2006) from large registries have shown a decrease in the rate of cardiogenic shock by as much as 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16329/abstract/4,16,17\">",
"     4,16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, three nationwide French registries conducted five years apart and including 7531 individuals were used to evaluate the incidence of and outcomes after cardiogenic shock in the setting of MI (STEMI and NSTEMI) between 1995 and 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16329/abstract/18\">",
"     18",
"    </a>",
"    ]. The incidence decreased significantly from 6.9 percent in 1995 to 5.7 percent in 2005. Over this period, mortality fell from 70 to 51 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe dysfunction of the left ventricle (LV) is the most common presentation of cardiogenic shock in the setting of acute myocardial infarction (MI) (",
"    <a class=\"graphic graphic_table graphicRef69673 \" href=\"UTD.htm?18/21/18780\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16329/abstract/5,19\">",
"     5,19",
"    </a>",
"    ]. The majority of patients have an acute STEMI, but cardiogenic shock also occurs in approximately 2.5 percent of patients with a non-ST elevation myocardial infarction (NSTEMI) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16329/abstract/1,20,21\">",
"     1,20,21",
"    </a>",
"    ]. Severe dysfunction is often associated with an anterior MI, but may result from an infarct in any location, particularly in patients who have had a prior infarct.",
"   </p>",
"   <p>",
"    Severe extensive ischemia due to multivessel coronary artery disease can also result in shock with an infarct of any size. Autopsy studies in patients dying with cardiogenic shock due to acute MI have revealed that &ge;40 percent of the left ventricular myocardium is infarcted (old and new) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16329/abstract/22\">",
"     22",
"    </a>",
"    ]. Most patients have severe three vessel coronary disease on coronary angiography. Severe right ventricular (RV) failure is a cause of, or a major contributor to, cardiogenic shock in five percent of cases and is typically seen with an inferior MI [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16329/abstract/1\">",
"     1",
"    </a>",
"    ]. Such patients do not develop pulmonary congestion unless there is concurrent involvement of the left ventricle. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/57/922?source=see_link\">",
"     \"Right ventricular myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cardiogenic shock can also be caused by mechanical complications of MI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39225?source=see_link\">",
"     \"Mechanical complications of acute myocardial infarction\"",
"    </a>",
"    .) Causes include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute, severe mitral regurgitation resulting from rupture of a papillary muscle or chordae tendineae or severe papillary muscle dysfunction. This is more common in the setting of inferoposterior infarction but can occur with any infarct location. When left ventricular failure causes shock, associated mitral regurgitation is common. The SHOCK trial, which evaluated early revascularization for cardiogenic shock after acute MI, excluded patients with mechanical causes of shock; 39 percent had echocardiographic evidence of moderate or severe mitral regurgitation, which correlated with poorer survival [",
"      <a class=\"abstract\" href=\"UTD.htm?15/60/16329/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rupture of the interventricular septum after either an anterior or inferior infarction, with an acute left to right shunt.",
"     </li>",
"     <li>",
"      Cardiac tamponade due to either rupture of the left ventricular free wall or a hemorrhagic pericardial effusion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The frequency of these causes of cardiogenic shock complicating an acute MI was evaluated in a review of 1190 patients from the SHOCK registry [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16329/abstract/23\">",
"     23",
"    </a>",
"    ]. Left ventricular failure was responsible in 79 percent, severe mitral regurgitation in 7 percent, ventricular septal rupture in 4 percent, isolated right ventricular shock in 2 percent, tamponade in 1.4 percent, and other causes in 7 percent (eg, prior severe valvular disease, excess beta blocker or calcium channel blocker therapy, and shock resulting from a complication of cardiac catheterization).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Contributing factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, failure of the left or right ventricle (with or without one of the mechanical complications discussed above) to pump an adequate amount of blood is the primary cause of cardiogenic shock. However, patients with cardiogenic shock in the setting of acute MI, or those who are on the verge of developing it, may have other factors that contribute to hypotension:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemorrhagic shock due to treatment with fibrinolytic agents",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      anticoagulants. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link&amp;anchor=H69243084#H69243084\">",
"       \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\", section on 'Bleeding'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Septic shock in patients with indwelling catheters or suspected infectious foci. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37464?source=see_link\">",
"       \"Epidemiology, pathogenesis, and microbiology of intravascular catheter infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypovolemia from any cause including diuretic therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24457?source=see_link&amp;anchor=H30#H30\">",
"       \"Etiology, clinical manifestations, and diagnosis of volume depletion in adults\", section on 'Manifestations of shock'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Severe valvular heart disease with limited cardiac reserve, such as in critical aortic stenosis. These patients can present with cardiogenic shock with even a small infarction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3737?source=see_link\">",
"       \"Hemodynamics of valvular disorders as measured by cardiac catheterization\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21706?source=see_link\">",
"       \"Clinical features and evaluation of aortic stenosis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Severe bradycardia, due either to complete heart block or sinus bradycardia. Bradycardia can cause a low cardiac output and hypotension in the setting of an acute MI with impaired ventricular function. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3878?source=see_link&amp;anchor=H12#H12\">",
"       \"Sinus bradycardia\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rapid atrial arrhythmias, such as atrial fibrillation with rapid ventricular response or ventricular tachycardia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/28/6601?source=see_link&amp;anchor=H2#H2\">",
"       \"Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm\", section on 'Adverse hemodynamics in AF'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link\">",
"       \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The excessive use of blood pressure lowering medications such as nitrates, angiotensin converting enzyme inhibitors, beta or calcium channel blockers, diuretics, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older age, anterior MI, history of hypertension, diabetes mellitus, multivessel coronary artery disease, prior MI, systolic BP &lt;120 mmHg, heart rate &gt;90 beats per minute, diagnosis of heart failure on admission, ST-elevation MI (STEMI), and left bundle branch block on the electrocardiogram are predictors of cardiogenic shock complicating acute MI [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16329/abstract/1,24\">",
"     1,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon these and other variables, models have been devised for predicting the development of cardiogenic shock in patients with an MI [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16329/abstract/21,24\">",
"     21,24",
"    </a>",
"    ]. However, because of a low predictive ability, we do not recommend their use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardinal features of shock, irrespective of shock type, include clinical manifestations of hypoperfusion such as hypotension (which occurs in most patients), oliguria, abnormal mental status, cold clammy skin, and evidence of metabolic acidosis on laboratory testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=see_link&amp;anchor=H3#H3\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\", section on 'Types of shock'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=see_link&amp;anchor=H13#H13\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\", section on 'Cardinal findings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The \"classic\" patient with cardiogenic shock has severe systemic hypotension, signs of systemic hypoperfusion (eg, cool extremities, oliguria,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    alteration in mental status), and respiratory distress due to pulmonary congestion. However, not all patients present with this syndrome.",
"   </p>",
"   <p>",
"    As the mortality associated with cardiogenic shock in the setting of acute MI is high and as the ability of therapies to improve this outcome declines with delays, the clinical evaluation (history and physical examination, as well as early laboratory testing) should be carried out expeditiously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H343520804\">",
"    <span class=\"h2\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with acute MI who develop cardiogenic shock do so after initial presentation (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Time of onset'",
"    </a>",
"    below.) These individuals often complain of the acute onset of recurrent chest pain and difficulty breathing. On examination new or worsening hypotension, tachycardia, and tachypnea are often present. The following are variably present [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16329/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]: distended neck veins, coolness of the skin, rales, gallop rhythm or new heart murmur on examination, and decreased volume and intensity of the distal pulses. In the SHOCK trial registry pulmonary congestion was absent at presentation in about one-third of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16329/abstract/26\">",
"     26",
"    </a>",
"    ] and 5.2 percent did not have overt hypotension (defined as a systolic pressure below 90 mmHg) despite signs of peripheral hypoperfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16329/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical manifestations are often different in patients with predominant right ventricular shock, which usually occurs in the setting of an acute inferior wall MI. This disorder is characterized by the absence of pulmonary congestion and the presence of jugular venous distension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/57/922?source=see_link\">",
"     \"Right ventricular myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H343520811\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following laboratory abnormalities are seen in patients who present with cardiogenic shock in the setting of acute MI:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      New or recurrent electrocardiographic evidence of ischemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=see_link&amp;anchor=H12#H12\">",
"       \"Criteria for the diagnosis of acute myocardial infarction\", section on 'ECG'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      New or worsening pulmonary congestion on a chest radiograph. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7544?source=see_link\">",
"       \"Evaluation of acute decompensated heart failure\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7544?source=see_link&amp;anchor=H7#H7\">",
"       \"Evaluation of acute decompensated heart failure\", section on 'Chest radiography'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Evidence of metabolic acidosis: elevated lactate level and decreased serum bicarbonate. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=see_link\">",
"       \"Approach to the adult with metabolic acidosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Evidence of renal hypoperfusion: increasing blood urea nitrogen and creatinine. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42773?source=see_link\">",
"       \"Definition of acute kidney injury (acute renal failure)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Evidence of pump failure and associated mechanical complications on echocardiography. (See",
"      <a class=\"local\" href=\"#H694484061\">",
"       'Echocardiography'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Time of onset",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients who develop cardiogenic shock due to acute MI do so after hospital admission [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16329/abstract/12,13,20,21,27\">",
"     12,13,20,21,27",
"    </a>",
"    ]. Patients who develop delayed cardiogenic shock following MI often slip slowly into shock, with clinical evidence of a low cardiac output prior to the development of hypotension. The delay in the development of cardiogenic shock is likely due to the eventual failure of the initial compensatory mechanisms that protect against the adverse hemodynamic consequences of a large infarction and associated mechanical complications. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Etiology'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H2\">",
"     'Pathophysiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The time course was evaluated in a report from the GUSTO-I trial of 41,000 patients with acute MI who were treated with fibrinolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16329/abstract/13\">",
"     13",
"    </a>",
"    ]. The following observations were made with respect to cardiogenic shock:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Shock was present on admission in 0.8 percent at hospital presentation and an additional 5.3 percent developed shock after admission, either as a sudden event or as a gradual fall in blood pressure.",
"     </li>",
"     <li>",
"      Approximately 50 percent of patients who developed shock after admission did so within the first 24 hours after the infarct; most remaining cases occurred in the following days, with a few cases being delayed for up to one week. Similar findings were noted in the SHOCK trial in which the median time from MI to onset of cardiogenic shock was 5.5 hours and 75 percent of patients who developed shock did so within 24 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?15/60/16329/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The frequency and timing of delayed cardiogenic shock were also evaluated in GUSTO-IIb, which included patients with an ST elevation MI or a non-ST elevation ACS (MI or unstable angina), and the PURSUIT trial of patients with a non-ST elevation ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16329/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Shock developed significantly later among patients with a non-ST elevation ACS (median 76 to 94 hours versus 9.6 hours for those with an ST elevation MI).",
"   </p>",
"   <p>",
"    The development of late cardiogenic shock may be related to recurrent ischemia or reinfarction or to mechanical complications, such as rupture of the ventricular septum, ventricular free wall, or papillary muscle. The clinical presentation usually consists of recurrent chest pain, recurrent or new ST segment elevation, and hypotension; some patients, however, have the sudden onset of dyspnea rather than chest pain.",
"   </p>",
"   <p>",
"    Some cases of late cardiogenic shock are in part iatrogenic due, for example, to early intravenous beta blockade in those with multiple risk factors for shock (eg, age, increased heart rate, decreased blood pressure, Killip class &gt;1, prior hypertension, late time to treatment), the use of multiple blood pressure lowering drugs (eg, beta blockers, angiotensin converting enzyme inhibitors, nitrates, and diuretics), and overly vigorous therapy of acute pulmonary edema. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Contributing factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of cardiogenic shock in the setting of acute MI can be made or strongly suspected from clinical manifestations presented above, including a history of recurrent chest pain or difficulty breathing, and findings of hypotension (in most patients), hypoperfusion, and (generally) pulmonary congestion on examination. (See",
"    <a class=\"local\" href=\"#H343520804\">",
"     'History and physical examination'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    When a patient is strongly suspected of having cardiogenic shock, the diagnostic evaluation should be carried out in conjunction with resuscitative efforts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link&amp;anchor=H3#H3\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\", section on 'Early management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=see_link\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients suspected of cardiogenic shock, a repeat electrocardiogram and an echocardiogram should be performed immediately. The electrocardiogram may confirm the presence of recurrent ischemia, particularly in patients who have been reperfused and, in most cases, the echocardiogram can confirm the diagnosis. Patients in whom the diagnosis remains uncertain should undergo placement of a balloon-tipped pulmonary artery (Swan-Ganz) catheter. The hemodynamic profile obtained with this catheter will usually confirm or refute the diagnosis. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Hemodynamic monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Additional laboratory testing should include: complete blood count, chemistry screen (including assessment of renal function and electrolyte status), prothrombin and partial thromboplastin times, serial troponin measurements, and a chest radiograph.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H694484061\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The findings of severely depressed global left or right ventricular systolic function (or both), decreased stroke volume, and elevated filling pressures (determined by assessing right and left atrial pressures) on echocardiography support the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16329/abstract/1,28\">",
"     1,28",
"    </a>",
"    ]. In addition, the study can assess regional left and right ventricular function, and can detect the cause or contributing factors to cardiogenic shock such as pericardial fluid with tamponade (",
"    <a class=\"graphic graphic_movie graphicRef68383 \" href=\"UTD.htm?19/28/19918\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef57972 \" href=\"UTD.htm?15/3/15408\">",
"     movie 2",
"    </a>",
"    ), severe mitral regurgitation (",
"    <a class=\"graphic graphic_movie graphicRef63107 \" href=\"UTD.htm?8/37/8784\">",
"     movie 3",
"    </a>",
"    ), which may be seen with flail mitral leaflet (",
"    <a class=\"graphic graphic_movie graphicRef60709 \" href=\"UTD.htm?12/21/12628\">",
"     movie 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef64363 \" href=\"UTD.htm?16/48/17154\">",
"     movie 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef61846 \" href=\"UTD.htm?17/43/18099\">",
"     movie 6",
"    </a>",
"    ), ventricular septal rupture (",
"    <a class=\"graphic graphic_movie graphicRef69435 \" href=\"UTD.htm?42/34/43554\">",
"     movie 7",
"    </a>",
"    ), and proximal aortic dissection (",
"    <a class=\"graphic graphic_movie graphicRef69234 \" href=\"UTD.htm?0/19/304\">",
"     movie 8",
"    </a>",
"    ), which may cause aortic insufficiency",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tamponade. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/6/11369?source=see_link\">",
"     \"Role of echocardiography in acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/6/11369?source=see_link&amp;anchor=H12#H12\">",
"     \"Role of echocardiography in acute myocardial infarction\", section on 'Detecting complications after MI'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transthoracic echocardiography is usually performed initially. However, it may be difficult to obtain an adequate image with this modality in critically ill patients, particularly those supported by mechanical ventilation. In this setting, transesophageal echocardiography (TEE) may provide important information. There are, for example, cases in which moderate mitral regurgitation was visualized on transthoracic echocardiography but subsequent TEE revealed a flail mitral leaflet with severe mitral regurgitation. TEE may also more clearly demonstrate ventricular septal rupture with a shunt visualized by color flow Doppler (",
"    <a class=\"graphic graphic_movie graphicRef64363 \" href=\"UTD.htm?16/48/17154\">",
"     movie 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Hemodynamic monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients in whom the diagnosis of cardiogenic shock remains uncertain after evaluating the clinical data and results from an echocardiogram should undergo placement balloon-tipped pulmonary artery (Swan-Ganz) catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16329/abstract/6,28,29\">",
"     6,28,29",
"    </a>",
"    ]. Once placed, the catheter can be used for further management of the patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44199?source=see_link\">",
"     \"Pulmonary artery catheterization: Interpretation of tracings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25221?source=see_link\">",
"     \"Insertion of pulmonary artery catheters\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/51/26424?source=see_link\">",
"     \"Arterial catheterization techniques for invasive monitoring\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=see_link\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=see_link&amp;anchor=H19#H19\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\", section on 'Hemodynamic monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of cardiogenic shock is confirmed when the hemodynamic profile shows arterial hypotension (a persistent systolic blood pressure below 80 to 90 mmHg or a mean blood pressure 30 mmHg lower than the patient's baseline level), a severe reduction in the cardiac index (&lt;1.8 to 2.0",
"    <span class=\"nowrap\">",
"     L/",
"    </span>",
"    min per m",
"    <sup>",
"     2",
"    </sup>",
"    without support or &lt;2.0 to 2.2",
"    <span class=\"nowrap\">",
"     L/",
"    </span>",
"    min per m",
"    <sup>",
"     2",
"    </sup>",
"    with support), and an elevated pulmonary capillary wedge pressure (PCWP) above ~15 mmHg. An elevated PCWP is often present in patients with and without pulmonary congestion (24 versus 22 mmHg in the SHOCK registry) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16329/abstract/26\">",
"     26",
"    </a>",
"    ]. In some cases, a normal or borderline elevated PCWP is present initially and then becomes clearly elevated after a fluid challenge. &nbsp;",
"   </p>",
"   <p>",
"    Hemodynamic evaluation is also useful in assessing the degree of vasoconstriction or vasodilation and in identifying patients with low left-sided filling pressures due to inadequate intravascular volume or to right ventricular infarction, a setting in which right atrial pressure will be increased [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16329/abstract/28\">",
"     28",
"    </a>",
"    ]. Some patients have vasodilatory shock after MI [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16329/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Pathophysiology'",
"    </a>",
"    above.) Identification of these patients may influence therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=see_link\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H607023667\">",
"    <span class=\"h2\">",
"     Coronary angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;On occasion, coronary angiography (or repeat coronary arteriography) may contribute to the diagnostic evaluation. It should be performed in all patients with cardiogenic shock in whom acute myocardial infarction is suspected and who are candidates for revascularization with either percutaneous coronary intervention or coronary artery bypass graft surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16329/abstract/28\">",
"     28",
"    </a>",
"    ]. In addition all patients who have undergone reperfusion therapy with either fibrinolytic therapy of percutaneous coronary intervention should be evaluated for failure of reperfusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=see_link\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8634?source=see_link\">",
"     \"Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31721?source=see_link&amp;anchor=H1365940#H1365940\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Periprocedural management\", section on 'Intraaortic balloon counterpulsation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H607022041\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with diagnosed or suspected acute MI who have or develop symptoms and signs of hypoperfusion, shock is almost always due to a complication of the MI. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Etiology'",
"    </a>",
"    above.) The diagnosis of cardiogenic shock is usually confirmed with a bedside echocardiogram or (on occasion) hemodynamic monitoring. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    However, other clinical scenarios may mimic this presentation and fall into two general categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute MI with shock due to non-cardiac causes such as sepsis from an indwelling catheter or hypovolemia caused by overaggressive diuresis. The hemodynamic profile of patients with shock due to sepsis or hypovolemia generally differs from that of patients with cardiogenic shock (",
"      <a class=\"graphic graphic_table graphicRef73000 \" href=\"UTD.htm?17/34/17963\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Hemodynamic monitoring'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=see_link&amp;anchor=H19#H19\">",
"       \"Shock in adults: Types, presentation, and diagnostic approach\", section on 'Diagnostic approach'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiovascular diseases in which the primary problem is not acute MI (",
"      <a class=\"graphic graphic_table graphicRef69673 \" href=\"UTD.htm?18/21/18780\">",
"       table 2",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Stress-induced cardiomyopathy, also called transient left ventricular apical ballooning, takotsubo cardiomyopathy, and broken heart syndrome. This disorder is typically precipitated by intense psychologic stress and primarily occurs in postmenopausal women. The characteristic finding of apical ballooning is seen on left ventriculography or echocardiography with ST elevation on the surface electrocardiogram. Despite frequent hemodynamic compromise or even cardiogenic shock, almost all patients recover completely within one to four weeks. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30745?source=see_link\">",
"       \"Stress-induced (takotsubo) cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypertrophic cardiomyopathy or acute myopericarditis. These may present with any combination of chest pain, ST or T wave changes on an electrocardiogram suggestive of acute infarction, and an elevated troponin. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26889?source=see_link\">",
"       \"Clinical manifestations and diagnosis of myocarditis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pulmonary embolism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4456?source=see_link\">",
"       \"Overview of acute pulmonary embolism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute regurgitant valvular heart disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/35/20022?source=see_link\">",
"       \"Acute aortic regurgitation in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/45/28376?source=see_link\">",
"       \"Pathophysiology, clinical features, evaluation, and management of acute mitral regurgitation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute MI due to ascending aortic dissection. Shock in this setting can result from the infarction caused by occlusion of one or more coronary arteries, acute aortic insufficiency,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cardiac tamponade. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=see_link\">",
"       \"Clinical manifestations and diagnosis of aortic dissection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiogenic shock is a clinical condition resulting from inadequate tissue (end-organ) perfusion due to cardiac dysfunction; it occurs most often in the setting of acute myocardial infarction (MI). It is characterized by severe reduction in the cardiac index (&lt;1.8",
"      <span class=\"nowrap\">",
"       L/",
"      </span>",
"      min per m",
"      <sup>",
"       2",
"      </sup>",
"      &nbsp;without support or &lt;2.0 to 2.2",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      per m",
"      <sup>",
"       2",
"      </sup>",
"      &nbsp;with support) and elevated filling pressures of the left, right, or both, and is&nbsp;typically associated with persistent hypotension (systolic blood pressure &lt;80 to 90 mmHg or mean arterial pressure 30 mmHg lower than baseline).",
"      <br/>",
"      <br/>",
"      However, there is a spectrum of severity of cardiogenic shock and marked elevation of systemic vascular resistance may maintain blood pressure despite&nbsp;end organ hypoperfusion and low cardiac index. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with myocardial infarction, cardiac dysfunction is usually due to severe left ventricular (muscle) failure. However, mechanical complications, such as acute mitral regurgitation or rupture of either the ventricular septal or free walls may be contributive or causative. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with acute MI, cardiogenic shock usually develops after hospital admission. The clinical presentation often includes a history of recurrent chest pain or difficulty breathing. Findings on examination usually include hypotension, cool extremities, oliguria, alteration in mental status, cool clammy skin, and respiratory distress. There is evidence of metabolic acidosis (low serum bicarbonate and elevated serum lactate) on laboratory testing. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of cardiogenic shock after acute MI can be made or strongly suspected from the clinical manifestations presented above; an electrocardiogram showing evidence of new or recurrent myocardial ischemia is supportive. In most cases, the diagnosis can be confirmed with echocardiography. (See",
"      <a class=\"local\" href=\"#H694484061\">",
"       'Echocardiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other clinical scenarios may mimic the presentation of acute MI followed by cardiogenic shock and fall into two general categories: those with clinical events consistent with acute MI but in whom myocardial ischemia is not the primary event, such as acute myopericarditis or ascending aortic dissection; and those with other causes of shock in a patient with MI, such as line sepsis or hypovolemia due to overdiuresis. (See",
"      <a class=\"local\" href=\"#H607022041\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Echocardiography will often point to the diagnosis in the first group, although coronary angiography will usually refute (or support) a diagnosis of myocardial ischemia. Hemodynamic monitoring is used to identify other causes of shock. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Hemodynamic monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional testing should include a chest radiograph, complete blood count, chemistry screen (including assessment of renal function and electrolyte status), prothrombin and partial thromboplastin times, and serial troponin measurements. (See",
"      <a class=\"local\" href=\"#H343520811\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16329/abstract/1\">",
"      Reynolds HR, Hochman JS. Cardiogenic shock: current concepts and improving outcomes. Circulation 2008; 117:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16329/abstract/2\">",
"      Hochman JS. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation 2003; 107:2998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16329/abstract/3\">",
"      Kohsaka S, Menon V, Lowe AM, et al. Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock. Arch Intern Med 2005; 165:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16329/abstract/4\">",
"      Fox KA, Steg PG, Eagle KA, et al. Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA 2007; 297:1892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16329/abstract/5\">",
"      Hollenberg SM, Kavinsky CJ, Parrillo JE. Cardiogenic shock. Ann Intern Med 1999; 131:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16329/abstract/6\">",
"      Califf RM, Bengtson JR. Cardiogenic shock. N Engl J Med 1994; 330:1724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16329/abstract/7\">",
"      Stegman BM, Newby LK, Hochman JS, Ohman EM. Post-myocardial infarction cardiogenic shock is a systemic illness in need of systemic treatment: is therapeutic hypothermia one possibility? J Am Coll Cardiol 2012; 59:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16329/abstract/8\">",
"      Picard MH, Davidoff R, Sleeper LA, et al. Echocardiographic predictors of survival and response to early revascularization in cardiogenic shock. Circulation 2003; 107:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16329/abstract/9\">",
"      Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002; 53:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16329/abstract/10\">",
"      Neumann FJ, Ott I, Gawaz M, et al. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation 1995; 92:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16329/abstract/11\">",
"      Wildhirt SM, Dudek RR, Suzuki H, Bing RJ. Involvement of inducible nitric oxide synthase in the inflammatory process of myocardial infarction. Int J Cardiol 1995; 50:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16329/abstract/12\">",
"      Babaev A, Frederick PD, Pasta DJ, et al. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA 2005; 294:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16329/abstract/13\">",
"      Holmes DR Jr, Bates ER, Kleiman NS, et al. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1995; 26:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16329/abstract/14\">",
"      Hands ME, Rutherford JD, Muller JE, et al. The in-hospital development of cardiogenic shock after myocardial infarction: incidence, predictors of occurrence, outcome and prognostic factors. The MILIS Study Group. J Am Coll Cardiol 1989; 14:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16329/abstract/15\">",
"      Goldberg RJ, Samad NA, Yarzebski J, et al. Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med 1999; 340:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16329/abstract/16\">",
"      Jeger RV, Radovanovic D, Hunziker PR, et al. Ten-year trends in the incidence and treatment of cardiogenic shock. Ann Intern Med 2008; 149:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16329/abstract/17\">",
"      Goldberg RJ, Spencer FA, Gore JM, et al. Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective. Circulation 2009; 119:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16329/abstract/18\">",
"      Aissaoui N, Puymirat E, Tabone X, et al. Improved outcome of cardiogenic shock at the acute stage of myocardial infarction: a report from the USIK 1995, USIC 2000, and FAST-MI French nationwide registries. Eur Heart J 2012; 33:2535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16329/abstract/19\">",
"      Hochman JS, Boland J, Sleeper LA, et al. Current spectrum of cardiogenic shock and effect of early revascularization on mortality. Results of an International Registry. SHOCK Registry Investigators. Circulation 1995; 91:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16329/abstract/20\">",
"      Holmes DR Jr, Berger PB, Hochman JS, et al. Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation. Circulation 1999; 100:2067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16329/abstract/21\">",
"      Hasdai D, Harrington RA, Hochman JS, et al. Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation. J Am Coll Cardiol 2000; 36:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16329/abstract/22\">",
"      Alonso DR, Scheidt S, Post M, Killip T. Pathophysiology of cardiogenic shock. Quantification of myocardial necrosis, clinical, pathologic and electrocardiographic correlations. Circulation 1973; 48:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16329/abstract/23\">",
"      Hochman JS, Buller CE, Sleeper LA, et al. Cardiogenic shock complicating acute myocardial infarction--etiologies, management and outcome: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol 2000; 36:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16329/abstract/24\">",
"      Hasdai D, Califf RM, Thompson TD, et al. Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol 2000; 35:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16329/abstract/25\">",
"      Menon V, Slater JN, White HD, et al. Acute myocardial infarction complicated by systemic hypoperfusion without hypotension: report of the SHOCK trial registry. Am J Med 2000; 108:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16329/abstract/26\">",
"      Menon V, White H, LeJemtel T, et al. The clinical profile of patients with suspected cardiogenic shock due to predominant left ventricular failure: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries in cardiogenic shocK? J Am Coll Cardiol 2000; 36:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16329/abstract/27\">",
"      Webb JG, Sleeper LA, Buller CE, et al. Implications of the timing of onset of cardiogenic shock after acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol 2000; 36:1084.",
"     </a>",
"    </li>",
"    <li>",
"     Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16329/abstract/29\">",
"      Mueller HS, Chatterjee K, Davis KB, et al. ACC expert consensus document. Present use of bedside right heart catheterization in patients with cardiac disease. American College of Cardiology. J Am Coll Cardiol 1998; 32:840.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 44 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-76F9A528C7-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_60_16329=[""].join("\n");
var outline_f15_60_16329=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H607023030\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Contributing factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H343520804\">",
"      History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H343520811\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Time of onset",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H694484061\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Hemodynamic monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H607023667\">",
"      Coronary angiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H607022041\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/44\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/44|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/33/3603\" title=\"figure 1\">",
"      Pathophysiology of cardiogenic shock",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/44|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?19/28/19918\" title=\"movie 1\">",
"      Pericardial effusion with tamponade long axis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?15/3/15408\" title=\"movie 2\">",
"      Pericardial effusion with tamponade 4 chamber view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?8/37/8784\" title=\"movie 3\">",
"      Echo four chamber severe MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?12/21/12628\" title=\"movie 4\">",
"      Flail mitral valve four chamber echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?16/48/17154\" title=\"movie 5\">",
"      Flail mitral leaflet apical long axis echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?17/43/18099\" title=\"movie 6\">",
"      Flail mitral leaflet apical long axis color Doppler echo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?42/34/43554\" title=\"movie 7\">",
"      VSD after MI TEE with color Doppler",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?0/19/304\" title=\"movie 8\">",
"      Aortic dissection transesophageal echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/44|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/34/17963\" title=\"table 1\">",
"      Types of shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/21/18780\" title=\"table 2\">",
"      Causes cardiogenic shock",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/35/20022?source=related_link\">",
"      Acute aortic regurgitation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=related_link\">",
"      Approach to the adult with metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/51/26424?source=related_link\">",
"      Arterial catheterization techniques for invasive monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21706?source=related_link\">",
"      Clinical features and evaluation of aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=related_link\">",
"      Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=related_link\">",
"      Clinical manifestations and diagnosis of aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26889?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=related_link\">",
"      Criteria for the diagnosis of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42773?source=related_link\">",
"      Definition of acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37464?source=related_link\">",
"      Epidemiology, pathogenesis, and microbiology of intravascular catheter infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24457?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of volume depletion in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7544?source=related_link\">",
"      Evaluation of acute decompensated heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=related_link\">",
"      Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/28/6601?source=related_link\">",
"      Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3737?source=related_link\">",
"      Hemodynamics of valvular disorders as measured by cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25221?source=related_link\">",
"      Insertion of pulmonary artery catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8634?source=related_link\">",
"      Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39225?source=related_link\">",
"      Mechanical complications of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4456?source=related_link\">",
"      Overview of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23076?source=related_link\">",
"      Pathophysiology of heart failure: Left ventricular pressure-volume relationships",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/45/28376?source=related_link\">",
"      Pathophysiology, clinical features, evaluation, and management of acute mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31721?source=related_link\">",
"      Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Periprocedural management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=related_link\">",
"      Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44199?source=related_link\">",
"      Pulmonary artery catheterization: Interpretation of tracings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/57/922?source=related_link\">",
"      Right ventricular myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/6/11369?source=related_link\">",
"      Role of echocardiography in acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24744?source=related_link\">",
"      Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=related_link\">",
"      Shock in adults: Types, presentation, and diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3878?source=related_link\">",
"      Sinus bradycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30745?source=related_link\">",
"      Stress-induced (takotsubo) cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_60_16330="Geriatric bipolar disorder: Acute treatment";
var content_f15_60_16330=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Geriatric bipolar disorder: Acute treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/60/16330/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/60/16330/contributors\">",
"     Martha Sajatovic, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/60/16330/contributors\">",
"     Peijun Chen, MD, MPH, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/60/16330/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/60/16330/contributors\">",
"     Paul Keck, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/60/16330/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/60/16330/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/60/16330/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/60/16330/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H175102985\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features and treatment of older bipolar patients differ from those of younger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/1\">",
"     1",
"    </a>",
"    ]. Up to 25 percent of all bipolar patients are elderly [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/2\">",
"     2",
"    </a>",
"    ], and the absolute number of geriatric bipolar patients is expected to increase as the world&rsquo;s population ages over the next several decades [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews the acute treatment of geriatric bipolar disorder. The epidemiology, pathogenesis, clinical features, assessment, diagnosis, maintenance treatment, and prognosis of geriatric bipolar disorder are discussed separately, as are the clinical features, diagnosis, acute treatment, and maintenance treatment of bipolar disorder in mixed-age patients.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7545?source=see_link\">",
"       \"Geriatric bipolar disorder: Epidemiology, clinical features, assessment, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/4/22601?source=see_link\">",
"       \"Geriatric bipolar disorder: Maintenance treatment and prognosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19639?source=see_link\">",
"       \"Bipolar disorder in adults: Epidemiology and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38026?source=see_link\">",
"       \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/3/44088?source=see_link\">",
"       \"Bipolar disorder in adults: Pharmacotherapy for acute depression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/9/27802?source=see_link\">",
"       \"Bipolar disorder in adults: Maintenance treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87030370\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The minimum age used to define geriatric bipolar disorder is generally 60 years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/5\">",
"     5",
"    </a>",
"    ]. However, some authorities use an age cut-off of 50, 55, or 65 years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/6\">",
"     6",
"    </a>",
"    ]. Geriatric bipolar disorder includes both aging patients whose mood disorder presented earlier in life, and patients whose mood disorder presents for the first time in later life [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/1,7\">",
"     1,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bipolar disorder is characterized by episodes of major depression (",
"    <a class=\"graphic graphic_table graphicRef70852 \" href=\"UTD.htm?17/21/17756\">",
"     table 1",
"    </a>",
"    ), mania (",
"    <a class=\"graphic graphic_table graphicRef81976 \" href=\"UTD.htm?3/53/3932\">",
"     table 2",
"    </a>",
"    ), and hypomania (",
"    <a class=\"graphic graphic_table graphicRef70757 \" href=\"UTD.htm?22/39/23164\">",
"     table 3",
"    </a>",
"    ), as well as mixed episodes (major depression concurrent with mania) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/8\">",
"     8",
"    </a>",
"    ]. However, the clinical features of bipolar disorder are different for older and younger patients in that [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/1,9-12\">",
"     1,9-12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cognitive impairment is more common and severe in geriatric patients",
"     </li>",
"     <li>",
"      Comorbid general medical illnesses are more common in older patients",
"     </li>",
"     <li>",
"      Excessive sexual interest and behavior during manic or hypomanic episodes appear to be less common in older patients",
"     </li>",
"     <li>",
"      Comorbid anxiety and substance use disorders may be less common in geriatric patients",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical features and diagnosis of geriatric bipolar disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7545?source=see_link&amp;anchor=H7214018#H7214018\">",
"     \"Geriatric bipolar disorder: Epidemiology, clinical features, assessment, and diagnosis\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7545?source=see_link&amp;anchor=H1522594#H1522594\">",
"     \"Geriatric bipolar disorder: Epidemiology, clinical features, assessment, and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13749294\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H260424900\">",
"    <span class=\"h2\">",
"     Goal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of acute treatment for late-life bipolar mood episodes is remission, which is defined as resolution of the mood symptoms or improvement to the point that only one or two symptoms of mild intensity persist. If psychotic features (delusions or hallucinations) are also present, resolution of the psychosis is required for remission. For patients who do not achieve remission, a reasonable goal is response, which is defined as stabilization of the patient&rsquo;s safety and substantial improvement in the number, intensity, and frequency of psychotic and mood symptoms. Response can be quantified with standardized rating scales such as the Brief Psychiatric Rating Scale (assesses psychosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/13\">",
"     13",
"    </a>",
"    ], Young Mania Rating Scale (assesses mania) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/14\">",
"     14",
"    </a>",
"    ], and the Patient Health Questionnaire &ndash; Nine Item (assesses depression) (",
"    <a class=\"graphic graphic_table graphicRef59307 \" href=\"UTD.htm?14/12/14541\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/15\">",
"     15",
"    </a>",
"    ], but this is not standard clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13749301\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for geriatric bipolar patients begins with a psychiatric and general medical history, mental status and physical examination, and focused laboratory and imaging studies. The evaluation establishes the mood symptoms and comorbid disorders that require treatment, as well as any contraindications to treatment (eg, renal impairment and use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , or hepatic disease and use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    ). The assessment for late-life bipolar disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7545?source=see_link&amp;anchor=H1522610#H1522610\">",
"     \"Geriatric bipolar disorder: Epidemiology, clinical features, assessment, and diagnosis\", section on 'Assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment setting for geriatric bipolar disorder depends upon the type and severity of symptoms, comorbid psychopathology (eg, substance use disorder), level of psychosocial functioning, and available support. Hospitalization may be required for safety and stabilization, particularly for severely ill patients with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Suicidal ideation with a specific plan and intent",
"     </li>",
"     <li>",
"      Delusions or hallucinations that place the patient at imminent risk of coming to harm",
"     </li>",
"     <li>",
"      Substance dependence that is exacerbating the mood episode",
"     </li>",
"     <li>",
"      Impaired functioning (eg, inability to feed or clothe oneself) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Moderately ill patients with late-life bipolar disorder can be treated in a partial hospital (day) program or residential facility (eg, nursing home), including patients with suicidality that does not pose an imminent risk (eg, fleeting thoughts of killing oneself with vague or nonexistent plans and no intent). An outpatient clinic may be suitable for less acutely ill patients (eg, thoughts that family members would be better off if the patient was dead, with no plan or intent to commit suicide).",
"   </p>",
"   <p>",
"    Evidence for the efficacy of medications includes subgroup analyses of results for geriatric patients enrolled in randomized trials conducted with mixed-age adult bipolar patients (18 to 65 years). These studies generally show that response is comparable for older and younger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Other evidence consists of open-label prospective studies, retrospective studies, and case reports.",
"   </p>",
"   <p>",
"    Treatment of geriatric mania, bipolar major depression, and mixed episodes may require a combination of two psychotropic medications [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. In addition, mood episodes with psychotic symptoms generally require treatment with a second-generation antipsychotic such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    , either as monotherapy or combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Geriatric bipolar mood episodes secondary to a general medical condition are managed with concurrent treatment of the medical condition and mood symptoms. Mood episodes due to general medical conditions are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7545?source=see_link&amp;anchor=H99600145#H99600145\">",
"     \"Geriatric bipolar disorder: Epidemiology, clinical features, assessment, and diagnosis\", section on 'General medical conditions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Compared to younger patients, geriatric bipolar patients often require more vigilant monitoring of therapeutic and adverse medication effects [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/21\">",
"     21",
"    </a>",
"    ]. Hospitalized geriatric patients are monitored daily. Outpatients are commonly seen on a weekly basis until they have responded (ie, the number, intensity, and frequency of mood symptoms has improved by at least 50 percent) and have tolerated the medication regimen for two to four weeks. At that point the patient can be seen every two to four weeks until they remit. Patients who suffer a recurrence of mood (or psychotic) symptoms or develop new side effects may need to resume a more frequent schedule of visits, depending upon the severity of symptoms.",
"   </p>",
"   <p>",
"    Patients with geriatric bipolar depression may possibly benefit from adding group psychoeducation to pharmacotherapy. An open-label study evaluated a 12-week, adjunctive group psychoeducation program focused upon medication adherence in 21 older bipolar patients, most of whom were depressed [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/22\">",
"     22",
"    </a>",
"    ]. Clinically small to moderate improvement in depressive symptoms occurred in the 16 patients who completed the study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13749308\">",
"    <span class=\"h2\">",
"     Pharmacologic issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should &ldquo;start low and go slow&rdquo; when prescribing medications for geriatric bipolar patients, especially frail, medically compromised patients who have difficulty tolerating medications [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. Comorbid diseases, concomitant medications, and age-related physiologic changes can alter a drug&rsquo;s pharmacodynamics and pharmacokinetics, which often affect therapeutic and adverse responses. Thus, pharmacotherapy generally requires:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Starting the drug at a low dose",
"     </li>",
"     <li>",
"      Increasing the dose by small increments every one to seven days",
"     </li>",
"     <li>",
"      Caution regarding side effects",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Older bipolar patients taking multiple medications due to comorbid illnesses are at risk for drug-drug interactions. Specific interactions of any particular drug with other medications may be determined by using the drug interactions tool (Lexi-Interact Online) included in UpToDate. This tool can be accessed from the UpToDate online search page or through the individual drug information topics in the section on Drug interactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13749322\">",
"    <span class=\"h2\">",
"     Manic, hypomanic, and mixed episodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacotherapy is generally used for geriatric manic, hypomanic, and mixed episodes. Despite clinical differences among these types of mood episodes, for the purpose of treatment they are considered to be similar and thus treated with the same medications [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/23,26,27\">",
"     23,26,27",
"    </a>",
"    ]. For refractory mania or mixed episodes, electroconvulsive therapy (ECT) can be beneficial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1137967\">",
"    <span class=\"h3\">",
"     First line medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;First-line medications for geriatric mania, hypomania, and mixed episodes include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    , based upon randomized trials in mixed-age adults [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/28-31\">",
"     28-31",
"    </a>",
"    ] and other studies in older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/1,18,19,21\">",
"     1,18,19,21",
"    </a>",
"    ]. No head-to-head trials have compared these drugs in the elderly. The specific choice is thus based upon other factors, including past response to medications, side effect profiles, comorbid general medical conditions, potential for drug-drug interactions, patient preference, and cost. Clinicians can generally expect that approximately 50 to 60 percent of patients will respond to a first-line treatment, based upon study results [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/16,21,32\">",
"     16,21,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       Quetiapine",
"      </a>",
"      &ndash; In elderly bipolar patients, quetiapine is usually started at 12.5 to 25 mg once daily or 25 to 50 mg per day in two divided doses [",
"      <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/18,33\">",
"       18,33",
"      </a>",
"      ]. The dose is then increased every two to five days by increments equal to the starting dose to reach the target dose of 100 to 300 mg per day, taken in two divided doses. For patients who neither respond to 300 mg per day nor are troubled by side effects, the dose may be increased up to 800 mg per day [",
"      <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/16\">",
"       16",
"      </a>",
"      ]. However, many patients will not tolerate higher doses due to sedation and orthostasis.",
"      <br/>",
"      <br/>",
"      Common side effects observed in older manic patients treated with quetiapine include dry mouth, sedation, postural hypotension and dizziness, dyslipidemia, hyperglycemia, and weight gain [",
"      <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/1,16\">",
"       1,16",
"      </a>",
"      ]. Fall risk may be increased in elderly people with sedation and postural hypotension. In addition, second-generation antipsychotics are associated with an increased risk of death in elderly patients treated for dementia-related psychosis (primarily cardiovascular events or infections) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/34\">",
"       34",
"      </a>",
"      ]; some authorities believe this risk may extend to late-life bipolar disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/24\">",
"       24",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Evidence of efficacy includes a pooled analysis of two 12-week randomized trials that compared quetiapine with placebo in mixed-age manic patients [",
"      <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/16\">",
"       16",
"      </a>",
"      ]. In the subgroup of 59 older patients, symptoms improved significantly more with quetiapine (modal dose 550 mg per day) than placebo. This was consistent with the finding that quetiapine was superior to placebo in younger patients. Among older patients, withdrawal from treatment due to adverse effects occurred in more patients who received quetiapine than placebo (25 versus 10 percent).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       Olanzapine",
"      </a>",
"      <strong>",
"      </strong>",
"      &ndash; Olanzapine is usually started at 2.5 to 5 mg once daily in elderly bipolar patients [",
"      <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/18,33\">",
"       18,33",
"      </a>",
"      ]. The dose is then increased every two to five days by increments equal to the starting dose, to reach the target dose of 5 to 15 mg per day. For patients who neither respond to 15 mg per day nor are troubled by side effects, the dose may be increased up to 20 mg per day.",
"      <br/>",
"      <br/>",
"      Olanzapine can cause sedation and falls, as well as weight gain, dyslipidemia, and hyperglycemia [",
"      <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/1\">",
"       1",
"      </a>",
"      ]. In addition, second-generation antipsychotics are associated with an increased risk of death in elderly patients treated for dementia-related psychosis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/34\">",
"       34",
"      </a>",
"      ]; some authorities believe this risk may extend to late-life bipolar disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/24\">",
"       24",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Evidence of efficacy includes a pooled analysis of three randomized trials (61 acutely manic older patients) lasting three weeks, which found that symptoms improved more with olanzapine than placebo (not tested statistically) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/32\">",
"       32",
"      </a>",
"      ]. This is consistent with the finding that olanzapine is efficacious in younger patients [",
"      <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       Lithium",
"      </a>",
"      <strong>",
"      </strong>",
"      &ndash; Lithium is usually started at 150 mg once or twice daily in elderly bipolar patients and increased every one to five days as tolerated [",
"      <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/33,36,37\">",
"       33,36,37",
"      </a>",
"      ]. The half-life of lithium increases to approximately 28 to 36 hours as patients get older; elderly patients thus generally require smaller doses to reach and maintain a steady serum level than do younger patients.",
"      <br/>",
"      <br/>",
"      The target dose is determined by 12-hour serum trough levels that should be drawn five to seven days after each dose increase. Target doses greater than 900 to 1200 mg per day are rarely required, and some patients 80 years or older may have therapeutic lithium levels with doses as low as 225 to 300 mg per day. A study of 56 geriatric bipolar patients who recovered from their mood episode with lithium found that the mean daily dose was 689 mg [",
"      <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/18\">",
"       18",
"      </a>",
"      ]. Lithium serum concentrations and laboratory testing are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/3/43065?source=see_link&amp;anchor=H182696765#H182696765\">",
"       \"Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects\", section on 'Lithium dose and serum concentrations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/3/43065?source=see_link&amp;anchor=H182696800#H182696800\">",
"       \"Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects\", section on 'Laboratory tests and monitoring'",
"      </a>",
"      .) The elderly are at greater risk for lithium toxicity than younger patients. Absorption of lithium is usually not changed by aging, but excretion is typically less in the elderly because the glomerular filtration rate is decreased [",
"      <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/36\">",
"       36",
"      </a>",
"      ]. In addition, older patients generally have a low volume of lithium distribution caused by reductions in lean body mass and total body water. Lithium side effects observed in older bipolar patients include ataxia, tremor, cognitive impairment, gastrointestinal distress, weight gain, polyuria, polydipsia, peripheral edema, hypothyroidism, rash, and worsening of arthritis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/1\">",
"       1",
"      </a>",
"      ]. Additional information about lithium toxicity and side effects is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/3/43065?source=see_link&amp;anchor=H182696786#H182696786\">",
"       \"Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects\", section on 'Lithium toxicity'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Drug-drug interactions involving lithium can increase the risk of adverse effects and toxicity because lithium has a narrow therapeutic index. Specific interactions of lithium with other medications may be determined by using the drug interactions tool (Lexi-Interact Online) included in UpToDate. This tool can be accessed from the UpToDate online search page or through the individual drug information topics in the section on Drug interactions.",
"      <br/>",
"      <br/>",
"      Evidence of efficacy includes a review of four open-label studies (137 geriatric bipolar patients) that found mania improved in 66 percent of patients treated with lithium [",
"      <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"       Valproate",
"      </a>",
"      <strong>",
"       (Divalproex)",
"      </strong>",
"      &ndash; Valproate is usually started at 125 to 250 mg per day in elderly bipolar patients and increased by the same amount every one to five days [",
"      <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/36\">",
"       36",
"      </a>",
"      ]. The target dose is generally determined by 12-hour serum trough levels of both total and free valproate, which should be drawn two to five days after each dose increase. We suggest that valproate be dosed to achieve a total serum level of 65 to 100",
"      <span class=\"nowrap\">",
"       mcg/mL,",
"      </span>",
"      although some elderly will not tolerate the higher ranges [",
"      <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/38,39\">",
"       38,39",
"      </a>",
"      ]. The half-life and free-plasma fraction of valproate may increase with age [",
"      <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/21\">",
"       21",
"      </a>",
"      ], and elderly patients generally require smaller doses to reach and maintain a steady serum level than do younger patients. The target dose is generally 500 to 1500 mg per day [",
"      <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/33,36\">",
"       33,36",
"      </a>",
"      ]. In a study of 76 geriatric bipolar patients who recovered from their mood episode with valproate, the mean daily dose was 956 mg per day [",
"      <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/18\">",
"       18",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Common side effects in older geriatric bipolar patients include gastrointestinal distress, sedation, weight gain, and hand tremor [",
"      <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/40,41\">",
"       40,41",
"      </a>",
"      ]. Additional information about valproate side effects is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=see_link&amp;anchor=H19#H19\">",
"       \"Pharmacology of antiepileptic drugs\", section on 'Valproate'",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"       \"Valproate: Drug information\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Evidence of efficacy includes a review of five open-label studies (137 geriatric bipolar patients) that found mania improved in 59 percent of patients treated with valproate [",
"      <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/21\">",
"       21",
"      </a>",
"      ]. In addition, a post-hoc, pooled analysis of three randomized trials lasting three weeks found that in 45 acutely manic older patients, symptoms improved more with valproate than placebo (not tested statistically) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For geriatric bipolar patients who do not respond to treatment with one first-line medication within four weeks of reaching the target dose, or do not tolerate the drug, we suggest tapering and discontinuing the failed medication over one to two weeks at the same time that another first-line medication is started and titrated up. (Response is defined as substantial improvement in the number, intensity, and frequency of symptoms.) The failed medication is generally tapered by the same amount for each dose decrease. As an example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    300 mg per day is decreased by 50 mg per day, every one to three days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175101727\">",
"    <span class=\"h3\">",
"     Resistant patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Geriatric manic, hypomanic, and mixed episodes often do not respond to treatment with two to four monotherapy trials of first line medications [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/16,21,32\">",
"     16,21,32",
"    </a>",
"    ]. For these resistant patients, we suggest combining",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    with a second-generation antipsychotic for four weeks, based upon randomized trials in mixed-age adults [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/28,42,43\">",
"     28,42,43",
"    </a>",
"    ]. However, lithium plus valproate is a reasonable alternative [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We generally use a medication combination consisting of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       Lithium",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      , or",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"       Valproate",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, there is no evidence of superior efficacy for any specific combination in treating manic, hypomanic, or mixed episodes. Selecting a combination is thus guided by side effect profiles, potential drug-drug interactions, comorbid general medical conditions, patient preference, and cost. Specific medication interactions that can occur may be determined using the drug interactions tool (Lexi-Interact Online) included in UpToDate. This tool can be accessed from the UpToDate online search page or through the individual drug information topics in the section on Drug interactions.",
"   </p>",
"   <p>",
"    For resistant geriatric bipolar patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    monotherapy for a manic, hypomanic, or mixed episode, we add",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    to their regimen. For resistant patients receiving quetiapine or olanzapine monotherapy, we add lithium or valproate to their regimen. The dose and side effects of lithium, valproate, quetiapine, and olanzapine are discussed separately. (See",
"    <a class=\"local\" href=\"#H1137967\">",
"     'First line medications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Resistant geriatric bipolar patients who do not respond to or tolerate one medication combination should be treated with a second medication combination. Generally,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    is switched to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    or vice versa. As an example, for patients who do not respond to lithium plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    within four weeks of reaching target doses, we suggest tapering and discontinuing lithium at the same time that valproate is started and titrated up. Lithium is generally tapered over one to two weeks by the same amount for each dose decrease (eg, lithium 900 mg per day is decreased by 300 mg per day, every one to three days).",
"   </p>",
"   <p>",
"    Conversely, for resistant geriatric patients who do not respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    within four weeks of reaching target doses, we suggest tapering and discontinuing valproate at the same time that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    is started and titrated up. Valproate is generally tapered over one to two weeks by the same amount for each dose decrease (eg, valproate 1000 mg per day is decreased by 250 mg per day, every one to three days).",
"   </p>",
"   <p>",
"    Although the antipsychotic (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ) is generally continued at the same dose when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    is switched to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    (or vice versa), it is also reasonable to switch the antipsychotic after lithium has been switched to valproate (or vice versa). The antipsychotic is generally tapered over one to two weeks by the same amount for each dose decrease (eg, olanzapine 15 mg per day is decreased by 5 mg per day, every one to three days), and at the same time, the other antipsychotic is started and titrated up.",
"   </p>",
"   <p>",
"    For resistant geriatric bipolar patients who do not tolerate medication combinations, we suggest monotherapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/18,33,46\">",
"     18,33,46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"       Aripiprazole",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Starting dose 2.5 to 5 mg once daily",
"     </li>",
"     <li>",
"      Target dose 5 to 15 mg once daily",
"     </li>",
"     <li>",
"      Maximum dose 30 per day",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"       Risperidone",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Starting dose 0.5 to 1 mg once daily or in two divided doses",
"     </li>",
"     <li>",
"      Target dose 1 to 4 mg once daily or in two divided doses",
"     </li>",
"     <li>",
"      Maximum dose 6 mg per day",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=see_link\">",
"       Ziprasidone",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Starting dose 20 mg once daily or 40 mg per day in two divided doses",
"     </li>",
"     <li>",
"      Target dose 80 to 120 mg per day, in two divided doses",
"     </li>",
"     <li>",
"      Maximum dose 160 mg per day",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To reach the target dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    , we suggest increasing the drug every two to five days by increments equal to the starting dose. At the same time, both drugs of the failed regimen are concurrently tapered and discontinued over one to two weeks. Each failed medication is decreased by the same amount each time the dose is decreased. As an example, if the patient is receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    900 mg per day and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    10 mg per day, lithium is decreased by 300 mg per day every one to three days, and olanzapine by 5 mg every one to three days.",
"   </p>",
"   <p>",
"    Second-generation antipsychotics are associated with an increased risk of death in elderly patients treated for dementia-related psychosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/34\">",
"     34",
"    </a>",
"    ]; some authorities believe this risk may extend to late-life bipolar disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/24\">",
"     24",
"    </a>",
"    ]. Information about other side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38026?source=see_link&amp;anchor=H2346270045#H2346270045\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\", section on 'Second-generation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1036587\">",
"    <span class=\"h3\">",
"     Refractory patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon clinical experience, geriatric manic, hypomanic, and mixed episodes generally respond to treatment with first-line medications or a medication combination. However, for refractory patients whose manic or mixed episode does not respond to four to eight medication trials, we suggest electroconvulsive therapy (ECT) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/1,24\">",
"     1,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ECT is generally safe and there are no absolute contraindications, even in patients whose general medical status is compromised [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/47\">",
"     47",
"    </a>",
"    ]. However, safety concerns regarding ECT necessitate preprocedure medical consultation. Adverse effects include cardiopulmonary events, aspiration pneumonia, fractures, dental and tongue injuries, headache, nausea, and cognitive impairment. Medical consultation prior to ECT is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21145?source=see_link\">",
"     \"Medical consultation for electroconvulsive therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Electrode placement and other aspects of ECT technique for treating geriatric bipolar disorder have not been standardized. Thus, ECT is typically administered with the same technique used for other indications and is generally given three times per week on alternating days. Most patients regardless of indication remit with 6 to 12 treatments, but some patients may require 20 or more. Additional information about ECT is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41305?source=see_link\">",
"     \"Overview of electroconvulsive therapy (ECT) for adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13128?source=see_link\">",
"     \"Technique for performing electroconvulsive therapy (ECT) in adults\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Although there is little evidence for the antimanic efficacy of ECT in geriatric patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/1\">",
"     1",
"    </a>",
"    ], several studies suggest that ECT is effective for mixed-age manic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/48\">",
"     48",
"    </a>",
"    ]. As an example, a review (mostly retrospective studies) found that among 589 manic patients treated with ECT, marked improvement occurred in 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/49\">",
"     49",
"    </a>",
"    ]. &nbsp; &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    A reasonable alternative to ECT for refractory geriatric mania, hypomania, or mixed episodes is a trial with a first-generation antipsychotic,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"     levetiracetam",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    . However, adverse effects often limit their use [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/21,36\">",
"     21,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among first-generation antipsychotics, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    , which is started at a dose of 0.5 to 2.0 mg daily, and increased every three to five days by the same amount to a target dose of 5 mg daily, and a maximum of 10 mg per day. Compared with second-generation antipsychotics, first-generation antipsychotics are more likely to cause extrapyramidal symptoms (EPS) and tardive dyskinesia, and their incidence increases with age [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/24\">",
"     24",
"    </a>",
"    ]. In addition, first-generation antipsychotics are associated with an increased risk of death in elderly patients treated for dementia-related psychosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/34\">",
"     34",
"    </a>",
"    ]; some authorities believe this risk may extend to late-life bipolar disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/24\">",
"     24",
"    </a>",
"    ]. Evidence for the efficacy of haloperidol includes a multiple treatments meta-analysis of randomized trials in mixed-age patients with a manic or mixed episode; haloperidol was more effective than any other antimanic agent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/31\">",
"     31",
"    </a>",
"    ]. Additional information about the dose and side effects of first-generation antipsychotics is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=see_link&amp;anchor=H272233794#H272233794\">",
"     \"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     Carbamazepine",
"    </a>",
"    is started at 100 mg once or twice per day, and is increased every three to five days by the same amount [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/33,36\">",
"     33,36",
"    </a>",
"    ]. The target dose is generally determined by 12-hour serum trough levels that should be drawn three to five days after each dose increase. Based upon clinical experience, we suggest that carbamazepine be dosed to achieve a serum level of 4 to 12",
"    <span class=\"nowrap\">",
"     mcg/mL,",
"    </span>",
"    which is typically achieved with a dose of 400 to 800 mg per day in two divided doses. A study of 12 geriatric bipolar patients who recovered from their mood episode with carbamazepine found that the mean daily dose was 608 mg per day [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/18\">",
"     18",
"    </a>",
"    ]. Adverse effects in geriatric bipolar patients include sedation, ataxia, blurred vision, nystagmus, and leukopenia, or more rarely agranulocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/36\">",
"     36",
"    </a>",
"    ]. Additional information about the side effects of carbamazepine is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38026?source=see_link&amp;anchor=H7#H7\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\", section on 'Carbamazepine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"     Levetiracetam",
"    </a>",
"    may possibly benefit geriatric bipolar patients with refractory mania, hypomania, or mixed episodes. A case series of six geriatric bipolar patients found that adjunctive levetiracetam (median dose 500 mg per day) improved manic symptoms and was well tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another alternative to ECT for geriatric patients with refractory manic, hypomanic, or mixed episodes is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    . The usual starting dose is 12.5 or 25 mg per day, which is increased by the same amount every day to 25 mg twice per day. Subsequently, the dose is increased by 25 mg per day every day as tolerated, to a target of approximately 150 mg twice per day. One concern with clozapine in elderly patients is fall risk related to sedation and postural hypotension. In addition, second-generation antipsychotics are associated with an increased risk of death in elderly patients treated for dementia-related psychosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/34\">",
"     34",
"    </a>",
"    ]; some authorities believe this risk may extend to late-life bipolar disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/24\">",
"     24",
"    </a>",
"    ]. In addition, clozapine can cause agranulocytosis and white blood cell counts need to be monitored. Evidence of its efficacy includes a case series of three refractory manic, geriatric patients who responded to clozapine (25 to 112.5 mg per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/51\">",
"     51",
"    </a>",
"    ]. Additional information about the pharmacology of clozapine, including side effects, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link&amp;anchor=H76524735#H76524735\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\", section on 'Clozapine'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13749357\">",
"    <span class=\"h2\">",
"     Bipolar major depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Geriatric bipolar major depression is typically treated with pharmacotherapy because it is easier to administer, more widely available, and more acceptable to patients compared with electroconvulsive therapy (ECT). However, refractory patients may benefit from ECT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H361190789\">",
"    <span class=\"h3\">",
"     First-line treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    as first-line treatment for geriatric bipolar depression [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/52,53\">",
"     52,53",
"    </a>",
"    ], based upon analyses of results for geriatric patients enrolled in randomized trials conducted with mixed-age adult bipolar patients (18 to 65 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/17\">",
"     17",
"    </a>",
"    ]. Clinicians can expect that approximately 40 to 50 percent of patients will respond to quetiapine, based upon study results [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In elderly bipolar patients,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    is usually started at 12.5 to 25 mg once daily or 25 to 50 mg per day in two divided doses [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/18,33\">",
"     18,33",
"    </a>",
"    ]. The dose is then increased every two to five days by increments equal to the starting dose to reach the target dose of 100 to 300 mg per day, taken in two divided doses. For patients who neither respond to 300 mg per day nor are troubled by side effects, the dose may be increased up to 600 mg per day [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/17\">",
"     17",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    In geriatric patients with bipolar major depression, quetiapine commonly causes dry mouth, sedation, dizziness, constipation, dyslipidemia, hyperglycemia, and weight gain [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/1,17\">",
"     1,17",
"    </a>",
"    ]. In addition, second-generation antipsychotics are associated with an increased risk of death (primarily cardiovascular events or infections) in elderly patients treated for dementia-related psychosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/34\">",
"     34",
"    </a>",
"    ]; some authorities believe this risk may extend to late-life bipolar disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence of efficacy includes a pooled analysis of two, eight-week randomized trials that compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    with placebo in mixed-age patients with bipolar major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/17\">",
"     17",
"    </a>",
"    ]. In the subgroup of 72 older patients, remission occurred more often with quetiapine 300 or 600 mg per day than placebo (45 and 48 versus 28 percent of patients). Although the differences between active treatment and placebo were not statistically significant, the results were consistent with the finding in younger patients that remission occurred significantly more often with quetiapine 300 or 600 mg than placebo. Among the older patients, withdrawal from treatment was comparable for quetiapine 300 mg per day and placebo (29 versus 30 percent of patients), but was greater for quetiapine 600 mg per day than placebo (48 versus 30 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H361190867\">",
"    <span class=\"h3\">",
"     Treatment resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Geriatric bipolar major depression often does not respond to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/17\">",
"     17",
"    </a>",
"    ]. For these resistant patients, we suggest switching to a second-line drug regimen, consisting of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/1,24,54-60\">",
"     1,24,54-60",
"    </a>",
"    ]. No head-to-head trials have compared the efficacy of these drugs for treating geriatric bipolar depression. The choice thus depends upon prior response to medications, side effect profiles, comorbid general medical conditions, potential for drug-drug interactions, patient preference, and cost.",
"   </p>",
"   <p>",
"    To switch drugs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    is tapered and discontinued over one to two weeks while at the same time a new drug regimen is started and titrated up. We generally taper quetiapine by the same amount for each dose decrease. As an example, quetiapine 300 mg per day is decreased by 50 mg per day, every one to three days.",
"   </p>",
"   <p>",
"    The starting dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    in elderly bipolar patients is 25 mg per day for two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/33,61\">",
"     33,61",
"    </a>",
"    ]. The dose is then increased to 25 mg twice daily for the next two weeks. Thereafter, the dose can be increased by 25 to 50 mg per day, one week at a time for each increase. This slow titration reduces the risk of serious and life-threatening skin rashes, such as Stevens-Johnson syndrome. The target dose is usually 100 to 200 mg per day, taken in two divided doses. A study of 41 geriatric bipolar patients who recovered from their mood episode with lamotrigine found that the mean daily dose was 163 mg per day [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence for the efficacy of adjunctive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    (mean daily dose 151 mg per day) includes a 12-week, open-label study in 57 geriatric patients with bipolar major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/61\">",
"     61",
"    </a>",
"    ]. Baseline depressive symptoms and psychosocial functioning improved significantly and remission occurred in 57 percent. Withdrawal from treatment due to adverse events occurred in 11 percent; side effects included benign rash, reduced or increased sleep duration, weight loss or weight gain, fatigue, and unsteady gait.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     Fluoxetine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    can efficaciously treat bipolar major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/62\">",
"     62",
"    </a>",
"    ]. A randomized trial (N = 437 mixed-age adults) found that remission occurred in more patients who received fluoxetine plus olanzapine than placebo (49 versus 25 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/54\">",
"     54",
"    </a>",
"    ]. For geriatric patients, we suggest starting fluoxetine at 10 mg per day and increasing the dose by the same amount every four weeks, to a target dose of 20 mg per day. Possible side effects include sedation, insomnia, weight loss or weight gain, abnormal bleeding, bone loss, and fractures. Given its long half life, fluoxetine should be used carefully in older adults. Although use of other antidepressants is not supported by high-quality evidence, we have successfully used either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/56/25481?source=see_link\">",
"     escitalopram",
"    </a>",
"    10 to 20 mg per day or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    37.5 mg to 225 mg per day. The dose and side effects of olanzapine are discussed elsewhere in the topic, and additional information about fluoxetine is discussed separately. (See",
"    <a class=\"local\" href=\"#H361190789\">",
"     'First-line treatment'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=see_link\">",
"     \"Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/57\">",
"     57",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/55\">",
"     55",
"    </a>",
"    ] can each effectively treat geriatric bipolar major depression. The dose and side effects of lithium and valproate are discussed elsewhere in this topic. (See",
"    <a class=\"local\" href=\"#H1137967\">",
"     'First line medications'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p>",
"    For geriatric bipolar depression that does not respond to treatment with one second-line medication regimen within four to eight weeks of reaching the target dose, we suggest tapering and discontinuing the failed regimen over one to two weeks at the same time that another second-line regimen is started and titrated up. The failed regimen is generally tapered by the same amount for each dose decrease. As an example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    150 mg per day is decreased by 50 mg per day, every one to three days. For patients who discontinue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    , both drugs are tapered concurrently.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1289836\">",
"    <span class=\"h3\">",
"     Refractory major depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Geriatric bipolar major depression often does not respond to pharmacotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/17,55,61\">",
"     17,55,61",
"    </a>",
"    ]. For refractory patients whose depression does not respond to three to five medication trials, we suggest electroconvulsive therapy (ECT) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/24,63,64\">",
"     24,63,64",
"    </a>",
"    ]. ECT is discussed separately. (See",
"    <a class=\"local\" href=\"#H1036587\">",
"     'Refractory patients'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although an open-label study with 20 geriatric bipolar patients suggested that adjunctive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    may possibly improve depressive symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/65\">",
"     65",
"    </a>",
"    ], we generally do not use it. Two randomized trials in mixed-age adults (N = 374 and 375) with bipolar major depression each found that remission with aripiprazole monotherapy was no better than placebo, and that aripiprazole caused more akathisia, insomnia, nausea, fatigue, restlessness, and dry mouth [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87478430\">",
"    <span class=\"h2\">",
"     Cognitive impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognition is commonly impaired in euthymic, geriatric bipolar patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]; however, no treatments have demonstrated any benefit. A case series of 12 euthymic, elderly bipolar patients with mild cognitive dysfunction found that adjunctive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/30/10726?source=see_link\">",
"     donepezil",
"    </a>",
"    did not improve cognition [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/69\">",
"     69",
"    </a>",
"    ]. Cognitive deficits in geriatric bipolar disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7545?source=see_link&amp;anchor=H1522530#H1522530\">",
"     \"Geriatric bipolar disorder: Epidemiology, clinical features, assessment, and diagnosis\", section on 'Cognitive impairment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13749378\">",
"    <span class=\"h1\">",
"     RECOVERY FROM MOOD EPISODES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Geriatric bipolar patients generally recover from their mood episodes, and appear to do so more often than younger patients. As an example, the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) found that recovery from mood episodes occurred in significantly more geriatric patients than younger patients (78 versus 67 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Geriatric bipolar disorder with late-onset (age 50 years or more) may have a better short-term course of illness than earlier-onset bipolar disorder that has persisted into later life [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/70\">",
"     70",
"    </a>",
"    ]. An observational study found that time to remission of manic or mixed episodes was significantly shorter for 141 late-onset patients compared with 323 earlier-onset patients (40 versus 56 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/60/16330/abstract/71\">",
"     71",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (See",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/5/4178?source=see_link\">",
"       \"Patient information: Bipolar disorder (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (The Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Beyond the Basics topics (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/55/39796?source=see_link\">",
"       \"Patient information: Bipolar disorder (manic depression) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These educational materials can be used as part of psychoeducational psychotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/9/27802?source=see_link&amp;anchor=H21#H21\">",
"     \"Bipolar disorder in adults: Maintenance treatment\", section on 'Psychoeducation'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    The National Institute of Mental Health also has educational material explaining the symptoms, course of illness, and treatment of bipolar disorder in a booklet entitled \"Bipolar Disorder,\" which is available online at the website",
"    <a class=\"external\" href=\"file://www.nimh.nih.gov/health/publications/bipolar-disorder/complete-index.shtml\">",
"     file://www.nimh.nih.gov/health/publications/bipolar-disorder/complete-index.shtml",
"    </a>",
"    or through a toll-free number, 866-615-6464. The web site also provides references, summaries of study results in language intended for the lay public, and information about clinical trials currently recruiting patients.",
"   </p>",
"   <p>",
"    More comprehensive information is provided in many books written for patients and family members, including The Bipolar Disorder Survival Guide: What You and Your Family Need to Know, written by David J. Miklowitz, PhD (published by The Guilford Press, 2002); An Unquiet Mind: A Memoir of Moods and Madness, written by Kay Jamison, PhD (published by Random House, 1995); and Treatment of Bipolar Illness: A Casebook for Clinicians and Patients, by RM Post, MD, and GS Leverich, LCSW (published by Norton Press, 2008).",
"   </p>",
"   <p>",
"    The Depression and Bipolar Support Alliance (",
"    <a class=\"external\" href=\"file://www.dbsalliance.org/\">",
"     file://www.dbsalliance.org",
"    </a>",
"    or 800-826-3632) is a national organization that educates members about bipolar disorder and how to cope with it. Other functions include increasing public awareness of the illness and advocating for more research and services. The organization is administered and maintained by patients and family members, and has local chapters.",
"   </p>",
"   <p>",
"    The National Alliance on Mental Illness (",
"    <a class=\"external\" href=\"file://www.nami.org/\">",
"     file://www.nami.org",
"    </a>",
"    or 800-950-6264) is a similarly structured organization devoted to education, support, and advocacy for patients with any mental illness. Bipolar disorder is one of their priorities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13749392\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The minimum age used to define geriatric bipolar disorder is generally 50 to 60 years. The clinical features of geriatric bipolar disorder differ from those of younger patients in that cognitive impairment and comorbid general medical illnesses are more common in geriatric patients, whereas comorbid anxiety and substance use disorders are less common in geriatric patients. (See",
"      <a class=\"local\" href=\"#H87030370\">",
"       'Definition'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7545?source=see_link&amp;anchor=H7214018#H7214018\">",
"       \"Geriatric bipolar disorder: Epidemiology, clinical features, assessment, and diagnosis\", section on 'Clinical features'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pharmacotherapy for geriatric bipolar disorder generally requires starting the drug at a low dose, increasing the drug by small increments that are separated by one to seven days, and caution regarding side effects. (See",
"      <a class=\"local\" href=\"#H13749308\">",
"       'Pharmacologic issues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For geriatric patients with an acute manic, hypomanic, or mixed episode, we suggest monotherapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      , rather than other medications (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The specific choice depends upon past response to medications, side effect profiles, comorbid general medical illnesses, potential for drug-drug interactions, patient preference, and cost. (See",
"      <a class=\"local\" href=\"#H1137967\">",
"       'First line medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For geriatric manic, hypomanic, or mixed episodes that do not respond to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      , we suggest combining lithium or valproate with quetiapine or olanzapine, rather than other medication regimens (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H175101727\">",
"       'Resistant patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For geriatric patients with bipolar major depression, we suggest initial treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      rather than other drugs or ECT (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H361190789\">",
"       'First-line treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For treatment of geriatric bipolar major depression that does not respond to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      , we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      , rather than other drugs (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H361190867\">",
"       'Treatment resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For geriatric patients with mania or a mixed episode that is refractory to treatment with four to eight medication trials, and for patients with refractory bipolar major depression that is refractory to three to five medication trials, we suggest electroconvulsive therapy (ECT) rather than additional pharmacotherapy trials (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1036587\">",
"       'Refractory patients'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1289836\">",
"       'Refractory major depression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Geriatric bipolar patients appear to recover from their mood episodes more often than younger patients. (See",
"      <a class=\"local\" href=\"#H13749378\">",
"       'Recovery from mood episodes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/1\">",
"      Sajatovic M, Chen P. Geriatric bipolar disorder. Psychiatr Clin North Am 2011; 34:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/2\">",
"      Sajatovic M, Blow FC, Ignacio RV, Kales HC. Age-related modifiers of clinical presentation and health service use among veterans with bipolar disorder. Psychiatr Serv 2004; 55:1014.",
"     </a>",
"    </li>",
"    <li>",
"     United Nations, Department of Economic and Social Affairs, Population Division, Population Estimates and Projections Section. file://esa.un.org/unpd/wpp/index.htm (Accessed on June 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/4\">",
"      Jeste DV, Alexopoulos GS, Bartels SJ, et al. Consensus statement on the upcoming crisis in geriatric mental health: research agenda for the next 2 decades. Arch Gen Psychiatry 1999; 56:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/5\">",
"      Young RC, Schulberg HC, Gildengers AG, et al. Conceptual and methodological issues in designing a randomized, controlled treatment trial for geriatric bipolar disorder: GERI-BD. Bipolar Disord 2010; 12:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/6\">",
"      Depp CA, Jeste DV. Bipolar disorder in older adults: a critical review. Bipolar Disord 2004; 6:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/7\">",
"      Prabhakar D, Balon R. Late-onset bipolar disorder: a case for careful appraisal. Psychiatry (Edgmont) 2010; 7:34.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/9\">",
"      Broadhead J, Jacoby R. Mania in old age: A first prospective study. Int J Geriatr Psychiatry 1990; 5:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/10\">",
"      Burt T, Prudic J, Peyser S, et al. Learning and memory in bipolar and unipolar major depression: effects of aging. Neuropsychiatry Neuropsychol Behav Neurol 2000; 13:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/11\">",
"      Young RC, Kiosses D, Heo M, et al. Age and ratings of manic psychopathology. Bipolar Disord 2007; 9:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/12\">",
"      Goldstein BI, Herrmann N, Shulman KI. Comorbidity in bipolar disorder among the elderly: results from an epidemiological community sample. Am J Psychiatry 2006; 163:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/13\">",
"      Rhoades HM, Overall JE. The semistructured BPRS interview and rating guide. Psychopharmacol Bull 1988; 24:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/14\">",
"      Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/15\">",
"      Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/16\">",
"      Sajatovic M, Calabrese JR, Mullen J. Quetiapine for the treatment of bipolar mania in older adults. Bipolar Disord 2008; 10:662.",
"     </a>",
"    </li>",
"    <li>",
"     Sajatovic M, Paulsson B. Quetiapine for the treatment of depressive episodes in adults aged 55 to 65 years with bipolar disorder. March 1-4, 2007. American Association of Geriatric Psychiatry Annual Meeting, New Orleans, LA.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/18\">",
"      Al Jurdi RK, Marangell LB, Petersen NJ, et al. Prescription patterns of psychotropic medications in elderly compared with younger participants who achieved a \"recovered\" status in the systematic treatment enhancement program for bipolar disorder. Am J Geriatr Psychiatry 2008; 16:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/19\">",
"      Gildengers AG, Mulsant BH, Begley AE, et al. A pilot study of standardized treatment in geriatric bipolar disorder. Am J Geriatr Psychiatry 2005; 13:319.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association Practice Guideline for the Treatment of Patients with Bipolar Disorder, Second Edition, 2002. file://www.psych.org/MainMenu/PsychiatricPractice/PracticeGuidelines_1.aspx (Accessed on August 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/21\">",
"      Young RC, Gyulai L, Mulsant BH, et al. Pharmacotherapy of bipolar disorder in old age: review and recommendations. Am J Geriatr Psychiatry 2004; 12:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/22\">",
"      Depp CA, Lebowitz BD, Patterson TL, et al. Medication adherence skills training for middle-aged and elderly adults with bipolar disorder: development and pilot study. Bipolar Disord 2007; 9:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/23\">",
"      American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/24\">",
"      Aziz R, Lorberg B, Tampi RR. Treatments for late-life bipolar disorder. Am J Geriatr Pharmacother 2006; 4:347.",
"     </a>",
"    </li>",
"    <li>",
"     Bipolar disorder: The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. NICE clinical guideline 38. July 2006. file://guidance.nice.org.uk/CG38 (Accessed on August 16, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/26\">",
"      Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry 2009; 10:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/27\">",
"      Yatham LN, Kennedy SH, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord 2005; 7 Suppl 3:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/28\">",
"      Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry 2007; 64:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/29\">",
"      Smith LA, Cornelius V, Warnock A, et al. Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials. Bipolar Disord 2007; 9:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/30\">",
"      Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009; 11:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/31\">",
"      Cipriani A, Barbui C, Salanti G, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 2011; 378:1306.",
"     </a>",
"    </li>",
"    <li>",
"     Beyer J, Siegal A, Kennedy J, et al. Olanzapine, divalproex, and placebo treatment: Non-head-to-head comparisons of older adult acute mania. Tenth Congress of the International Psychogeriatric Association, Nice, France, September 9-14, 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/33\">",
"      Sajatovic M, Fenn H, Chen P, et al. Treatment considerations in elderly bipolar patients. Clinical Approaches in Bipolar Disorder 2007; 6:54.",
"     </a>",
"    </li>",
"    <li>",
"     United States Food and Drug Administration, FDA Alert, 6/16/2008 file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm110212.htm (Accessed on August 17, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/35\">",
"      Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry 2000; 57:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/36\">",
"      Sajatovic M. Treatment of bipolar disorder in older adults. Int J Geriatr Psychiatry 2002; 17:865.",
"     </a>",
"    </li>",
"    <li>",
"     Labbate, LA, Fava, M, Rosenbaum, JF, et al. Drugs for treatment of bipolar disorders. In: Handbook of Psychiatric Drug Therapy, 6th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2010. p.110.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/38\">",
"      Chen ST, Altshuler LL, Melnyk KA, et al. Efficacy of lithium vs. valproate in the treatment of mania in the elderly: a retrospective study. J Clin Psychiatry 1999; 60:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/39\">",
"      Allen MH, Hirschfeld RM, Wozniak PJ, et al. Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. Am J Psychiatry 2006; 163:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/40\">",
"      Sajatovic M, Kales HC. Diagnosis and management of bipolar disorder with comorbid anxiety in the elderly. J Clin Psychiatry 2006; 67 Suppl 1:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/41\">",
"      Sajatovic M, Madhusoodanan S, Coconcea N. Managing bipolar disorder in the elderly: defining the role of the newer agents. Drugs Aging 2005; 22:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/42\">",
"      Perlis RH, Welge JA, Vornik LA, et al. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry 2006; 67:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/43\">",
"      Smith LA, Cornelius V, Warnock A, et al. Acute bipolar mania: a systematic review and meta-analysis of co-therapy vs. monotherapy. Acta Psychiatr Scand 2007; 115:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/44\">",
"      Maina G, Albert U, Salvi V, et al. Valproate or olanzapine add-on to lithium: an 8-week, randomized, open-label study in Italian patients with a manic relapse. J Affect Disord 2007; 99:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/45\">",
"      Reischies FM, Hartikainen J, Bergh&ouml;fer A. Initial lithium and valproate combination therapy in acute mania. Neuropsychobiology 2002; 46 Suppl 1:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/46\">",
"      Chen P, Korobkova I, Busby K, Sajatovic M. Managing late-life bipolar disorder: An update. Aging health 2011; 7:557.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association Task Force on Electroconvulsive Therapy. The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging. American Psychiatric Association, Washington, DC 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/48\">",
"      Black DW, Winokur G, Nasrallah A. Treatment of mania: a naturalistic study of electroconvulsive therapy versus lithium in 438 patients. J Clin Psychiatry 1987; 48:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/49\">",
"      Mukherjee S, Sackeim HA, Schnur DB. Electroconvulsive therapy of acute manic episodes: a review of 50 years' experience. Am J Psychiatry 1994; 151:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/50\">",
"      Kyomen HH. The use of levetiracetam to decrease mania in elderly bipolar patients. Am J Geriatr Psychiatry 2006; 14:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/51\">",
"      Shulman RW, Singh A, Shulman KI. Treatment of elderly institutionalized bipolar patients with clozapine. Psychopharmacol Bull 1997; 33:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/52\">",
"      Swartz HA, Thase ME. Pharmacotherapy for the treatment of acute bipolar II depression: current evidence. J Clin Psychiatry 2011; 72:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/53\">",
"      Nivoli AM, Colom F, Murru A, et al. New treatment guidelines for acute bipolar depression: a systematic review. J Affect Disord 2011; 129:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/54\">",
"      Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/55\">",
"      Bond DJ, Lam RW, Yatham LN. Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis. J Affect Disord 2010; 124:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/56\">",
"      Hilty DM, Brady KT, Hales RE. A review of bipolar disorder among adults. Psychiatr Serv 1999; 50:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/57\">",
"      Zornberg GL, Pope HG Jr. Treatment of depression in bipolar disorder: new directions for research. J Clin Psychopharmacol 1993; 13:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/58\">",
"      Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/59\">",
"      Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999; 60:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/60\">",
"      van der Loos ML, Mulder PG, Hartong EG, et al. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry 2009; 70:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/61\">",
"      Sajatovic M, Gildengers A, Al Jurdi RK, et al. Multisite, open-label, prospective trial of lamotrigine for geriatric bipolar depression: a preliminary report. Bipolar Disord 2011; 13:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/62\">",
"      Brown EB, McElroy SL, Keck PE Jr, et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2006; 67:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/63\">",
"      Bailine S, Fink M, Knapp R, et al. Electroconvulsive therapy is equally effective in unipolar and bipolar depression. Acta Psychiatr Scand 2010; 121:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/64\">",
"      Dubovsky SL. Treatment of bipolar depression. Psychiatr Clin North Am 2005; 28:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/65\">",
"      Sajatovic M, Coconcea N, Ignacio RV, et al. Aripiprazole therapy in 20 older adults with bipolar disorder: a 12-week, open-label trial. J Clin Psychiatry 2008; 69:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/66\">",
"      Thase ME, Jonas A, Khan A, et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 2008; 28:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/67\">",
"      Gildengers AG, Butters MA, Seligman K, et al. Cognitive functioning in late-life bipolar disorder. Am J Psychiatry 2004; 161:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/68\">",
"      Tsai SY, Lee HC, Chen CC, Huang YL. Cognitive impairment in later life in patients with early-onset bipolar disorder. Bipolar Disord 2007; 9:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/69\">",
"      Gildengers AG, Butters MA, Chisholm D, et al. A 12-week open-label pilot study of donepezil for cognitive functioning and instrumental activities of daily living in late-life bipolar disorder. Int J Geriatr Psychiatry 2008; 23:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/70\">",
"      Sajatovic M, Blow FC, Ignacio RV, Kales HC. New-onset bipolar disorder in later life. Am J Geriatr Psychiatry 2005; 13:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/60/16330/abstract/71\">",
"      Oostervink F, Boomsma MM, Nolen WA, EMBLEM Advisory Board. Bipolar disorder in the elderly; different effects of age and of age of onset. J Affect Disord 2009; 116:176.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16446 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-77.94.48.4-442DE206A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_60_16330=[""].join("\n");
var outline_f15_60_16330=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13749392\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H175102985\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87030370\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13749294\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H260424900\">",
"      Goal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13749301\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13749308\">",
"      Pharmacologic issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13749322\">",
"      Manic, hypomanic, and mixed episodes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1137967\">",
"      - First line medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H175101727\">",
"      - Resistant patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1036587\">",
"      - Refractory patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13749357\">",
"      Bipolar major depression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H361190789\">",
"      - First-line treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H361190867\">",
"      - Treatment resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1289836\">",
"      - Refractory major depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H87478430\">",
"      Cognitive impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13749378\">",
"      RECOVERY FROM MOOD EPISODES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13749392\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/16446\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/16446|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/21/17756\" title=\"table 1\">",
"      DSM-IV-TR diagnostic criteria for major depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/53/3932\" title=\"table 2\">",
"      DSM-IV-TR diagnostic criteria for mania",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/39/23164\" title=\"table 3\">",
"      DSM-IV-TR diagnostic criteria for hypomania",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/12/14541\" title=\"table 4\">",
"      PHQ-9 questionnaire",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/3/43065?source=related_link\">",
"      Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19639?source=related_link\">",
"      Bipolar disorder in adults: Epidemiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/9/27802?source=related_link\">",
"      Bipolar disorder in adults: Maintenance treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/3/44088?source=related_link\">",
"      Bipolar disorder in adults: Pharmacotherapy for acute depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38026?source=related_link\">",
"      Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=related_link\">",
"      First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7545?source=related_link\">",
"      Geriatric bipolar disorder: Epidemiology, clinical features, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/4/22601?source=related_link\">",
"      Geriatric bipolar disorder: Maintenance treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21145?source=related_link\">",
"      Medical consultation for electroconvulsive therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41305?source=related_link\">",
"      Overview of electroconvulsive therapy (ECT) for adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/5/4178?source=related_link\">",
"      Patient information: Bipolar disorder (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/55/39796?source=related_link\">",
"      Patient information: Bipolar disorder (manic depression) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=related_link\">",
"      Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13128?source=related_link\">",
"      Technique for performing electroconvulsive therapy (ECT) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=related_link\">",
"      Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=related_link\">",
"      Valproate: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_60_16331="United States birth data by delivery type";
var content_f15_60_16331=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70509&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70509&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Morbidity and mortality data by delivery type for the United States, 1995-1998 (rates are per 10,000 deliveries)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Outcome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Unassisted",
"       </td>",
"       <td class=\"subtitle1\">",
"        Forceps delivery",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vacuum delivery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neonatal death",
"       </td>",
"       <td>",
"        3.7",
"       </td>",
"       <td>",
"        5.0",
"       </td>",
"       <td>",
"        4.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Birth injury",
"       </td>",
"       <td>",
"        21.4",
"       </td>",
"       <td>",
"        109.1",
"       </td>",
"       <td>",
"        76.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neonatal seizures",
"       </td>",
"       <td>",
"        5.0",
"       </td>",
"       <td>",
"        8.7",
"       </td>",
"       <td>",
"        6.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Assisted ventilation &lt;30 minutes",
"       </td>",
"       <td>",
"        147",
"       </td>",
"       <td>",
"        293",
"       </td>",
"       <td>",
"        250",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Demissie K, Rhoads GG, Smulian JC, et al. BMJ 2004; 329:24.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_60_16331=[""].join("\n");
var outline_f15_60_16331=null;
var title_f15_60_16332="Acetaminophen toxicity";
var content_f15_60_16332=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57032&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57032&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Stages of acute acetaminophen intoxication",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Stage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Hours after ingestion",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" rowspan=\"3\">",
"        I",
"       </td>",
"       <td rowspan=\"3\">",
"        0.5 to 24 hours",
"       </td>",
"       <td>",
"        Nausea, vomiting, diaphoresis, pallor, lethargy, and malaise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Some patients remain asymptomatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laboratory studies are typically normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" rowspan=\"7\">",
"        II&nbsp;&nbsp;",
"       </td>",
"       <td rowspan=\"7\">",
"        24 to 72 hours",
"       </td>",
"       <td>",
"        Stage I symptoms resolve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatotoxicity and nephrotoxicity become evident",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Right upper quadrant pain, liver enlargement and tenderness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elevation of aminotransferases occurs within 36 hours of ingestion in patients with hepatic injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elevation of prothrombin time (PT) and internationalized ratio of PT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oliguria, abnormalities of renal function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elevation of serum amylase with or without clinical pancreatitis may occur",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" rowspan=\"5\">",
"        III",
"       </td>",
"       <td rowspan=\"5\">",
"        72 to 96 hours",
"       </td>",
"       <td>",
"        Liver enzyme and function abnormalities peak (enzymes may be &gt;10,000 IU/L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recurrence of Stage I symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jaundice, hepatic encephalopathy, hyperammonemia, bleeding diathesis, hypoglycemia, lactic acidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal failure, the incidence of which is related to the severity of intoxication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Death, from multi-organ failure, occurs most commonly in this stage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" rowspan=\"3\">",
"        IV",
"       </td>",
"       <td rowspan=\"3\">",
"        4 to 14 days",
"       </td>",
"       <td>",
"        Recovery phase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptoms and laboratory values may not normalize for several weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Histologic recovery lags behind clinical recovery and may take up to three months",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_60_16332=[""].join("\n");
var outline_f15_60_16332=null;
var title_f15_60_16333="Anal cancer TNM stage";
var content_f15_60_16333=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F72273&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F72273&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    TNM staging for anal cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Primary tumor (T)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TX",
"       </td>",
"       <td colspan=\"3\">",
"        Primary tumor cannot be assessed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T0",
"       </td>",
"       <td colspan=\"3\">",
"        No evidence of primary tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tis",
"       </td>",
"       <td colspan=\"3\">",
"        Carcinoma in situ (Bowen's disease, high-grade squamous intraepithelial lesion (HSIL), anal intraepithelial neoplasia II-III (AIN II-III))",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T1",
"       </td>",
"       <td colspan=\"3\">",
"        Tumor 2 cm or less in greatest dimension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T2",
"       </td>",
"       <td colspan=\"3\">",
"        Tumor more than 2 cm but not more than 5 cm in greatest dimension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T3",
"       </td>",
"       <td colspan=\"3\">",
"        Tumor more than 5 cm in greatest dimension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T4",
"       </td>",
"       <td colspan=\"3\">",
"        Tumor of any size invades adjacent organ(s), eg, vagina, urethra, bladder*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Regional lymph nodes (N)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NX",
"       </td>",
"       <td colspan=\"3\">",
"        Regional lymph nodes cannot be assessed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N0",
"       </td>",
"       <td colspan=\"3\">",
"        No regional lymph node metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N1",
"       </td>",
"       <td colspan=\"3\">",
"        Metastasis in perirectal lymph node(s)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N2",
"       </td>",
"       <td colspan=\"3\">",
"        Metastasis in unilateral internal iliac and/or inguinal lymph node(s)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N3",
"       </td>",
"       <td colspan=\"3\">",
"        Metastasis in perirectal and inguinal lymph nodes and/or bilateral internal iliac and/or inguinal lymph nodes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Distant metastasis (M)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M0",
"       </td>",
"       <td colspan=\"3\">",
"        No distant metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M1",
"       </td>",
"       <td colspan=\"3\">",
"        Distant metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Anatomic stage/prognostic groups",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Tis",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        T1",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        II",
"       </td>",
"       <td>",
"        T2",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T3",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        IIIA",
"       </td>",
"       <td>",
"        T1",
"       </td>",
"       <td>",
"        N1",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T2",
"       </td>",
"       <td>",
"        N1",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T3",
"       </td>",
"       <td>",
"        N1",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T4",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        IIIB",
"       </td>",
"       <td>",
"        T4",
"       </td>",
"       <td>",
"        N1",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any T",
"       </td>",
"       <td>",
"        N2",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any T",
"       </td>",
"       <td>",
"        N3",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        Any T",
"       </td>",
"       <td>",
"        Any N",
"       </td>",
"       <td>",
"        M1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: cTNM is the clinical classification, pTNM is the pathologic classification.",
"    <div class=\"footnotes\">",
"     * Direct invasion of the rectal wall, perirectal skin, subcutaneous tissue, or the sphincter muscle(s) is not classified as T4.",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_60_16333=[""].join("\n");
var outline_f15_60_16333=null;
var title_f15_60_16334="Asthma severity 0 to 4 yrs";
var content_f15_60_16334=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61691%7EPULM%2F51579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61691%7EPULM%2F51579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classifying asthma severity in children 0-4 years of age",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"3\">",
"        Components of severity",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Classification of asthma severity (children 0-4 years of age)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" rowspan=\"2\">",
"        Intermittent",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"4\">",
"        Persistent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        Mild",
"       </td>",
"       <td class=\"subtitle3\">",
"        Moderate",
"       </td>",
"       <td class=\"subtitle3\">",
"        Severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Impairment",
"       </td>",
"       <td>",
"        Symptoms",
"       </td>",
"       <td>",
"        &le;2 days/week",
"       </td>",
"       <td>",
"        &gt;2 days/week but not daily",
"       </td>",
"       <td>",
"        Daily",
"       </td>",
"       <td>",
"        Throughout the day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nighttime awakenings",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1-2x/month",
"       </td>",
"       <td>",
"        3-4x/month",
"       </td>",
"       <td>",
"        &gt;1x/week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short-acting beta",
"        <sub>",
"         2",
"        </sub>",
"        -agonist use for symptom control (not prevention of EIB)",
"       </td>",
"       <td>",
"        &le;2 days/week",
"       </td>",
"       <td>",
"        &gt;2 days/week but not daily",
"       </td>",
"       <td>",
"        Daily",
"       </td>",
"       <td>",
"        Several times per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interference with normal activity",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Minor limitation",
"       </td>",
"       <td>",
"        Some limitation",
"       </td>",
"       <td>",
"        Extremely limited",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Risk",
"       </td>",
"       <td rowspan=\"4\">",
"        <strong>",
"         Exacerbations requiring oral systemic corticosteroids",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         0-1/year",
"        </strong>",
"       </td>",
"       <td colspan=\"3\">",
"        <strong>",
"         &ge;2 exacerbations in 6 months requiring oral steroids, or &ge;4 wheezing episodes/1 year lasting &gt;1 day AND risk factors for persistent asthma",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         Consider severity and interval since last exacerbation",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         Frequency and severity may fluctuate over time",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         Exacerbations of any severity may occur in patients in any severity category",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     Classifying severity in children who are not currently taking long-term control medication.",
"    </strong>",
"    Level of severity is determined by both impairment and risk. Assess impairment domain by caregiver's recall of previous 2-4 weeks. Assign severity to the most severe category in which any feature occurs. At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma severity. For treatment purposes, patients who had &ge;2 exacerbations requiring oral corticosteroids in the past 6 months, or &ge;4 wheezing episodes in the past year, and who have risk factors for persistent asthma may be considered the same as patients who have persistent asthma, even in the absence of impairment levels consistent with persistent asthma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classifying asthma severity in children 5-11 years of age",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"3\">",
"        Components of severity",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Classification of asthma severity (children 5-11 years of age)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" rowspan=\"2\">",
"        Intermittent",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"4\">",
"        Persistent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        Mild",
"       </td>",
"       <td class=\"subtitle3\">",
"        Moderate",
"       </td>",
"       <td class=\"subtitle3\">",
"        Severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Impairment",
"       </td>",
"       <td>",
"        Symptoms",
"       </td>",
"       <td>",
"        &le;2 days/week",
"       </td>",
"       <td>",
"        &gt;2 days/week but not daily",
"       </td>",
"       <td>",
"        Daily",
"       </td>",
"       <td>",
"        Throughout the day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nighttime awakenings",
"       </td>",
"       <td>",
"        &le;2x/month",
"       </td>",
"       <td>",
"        3-4x/month",
"       </td>",
"       <td>",
"        &gt;1x/week but not nightly",
"       </td>",
"       <td>",
"        Often 7x/week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short-acting beta",
"        <sub>",
"         2",
"        </sub>",
"        -agonist use for symptom control (not prevention of EIB)",
"       </td>",
"       <td>",
"        &le;2 days/week",
"       </td>",
"       <td>",
"        &gt;2 days/week but not daily",
"       </td>",
"       <td>",
"        Daily",
"       </td>",
"       <td>",
"        Several times per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interference with normal activity",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Minor limitation",
"       </td>",
"       <td>",
"        Some limitation",
"       </td>",
"       <td>",
"        Extremely limited",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lung function",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Normal FEV",
"         <sub>",
"          1",
"         </sub>",
"         between exacerbations",
"        </p>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         &gt;80 percent predicted",
"        </p>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         /FVC &gt;85 percent",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         = &gt;80 percent predicted",
"        </p>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         /FVC &gt;80 percent",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         = 60-80 percent predicted",
"        </p>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         /FVC = 75-80 percent",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         &lt;60 percent predicted",
"        </p>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         /FVC &lt;75 percent",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Risk",
"       </td>",
"       <td rowspan=\"4\">",
"        <strong>",
"         Exacerbations requiring oral systemic corticosteroids",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         0-1/year (see footnote)",
"        </strong>",
"       </td>",
"       <td colspan=\"3\">",
"        <strong>",
"         &ge;2 in 1 year (see footnote)",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         Consider severity and interval since last exacerbation",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         Frequency and severity may fluctuate over time for patients in any severity category",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         Relative annual risk of exacerbations may be related to FEV",
"         <sub>",
"          1",
"         </sub>",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     Classifying severity in children who are not currently taking long-term control medication.",
"    </strong>",
"    Level of severity is determined by both impairment and risk. Assess impairment domain by patient's/caregiver's recall of the previous 2-4 weeks and spirometry. Assign severity to the most severe category in which any feature occurs. At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma severity. In general, more frequent and intense exacerbations (eg, requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate greater underlying disease severity. For treatment purposes, patients who had &ge;2 exacerbations requiring oral systemic corticosteroids in the past year may be considered the same as patients who have persistent asthma, even in the absence of impairment levels consistent with persistent asthma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_60_16334=[""].join("\n");
var outline_f15_60_16334=null;
var title_f15_60_16335="Los Angeles grade B esophagitis";
var content_f15_60_16335=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74162&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74162&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 476px\">",
"   <div class=\"ttl\">",
"    Los Angeles grade B esophagitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 218px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Los Angeles grade B esophagitis: One or more mucosal breaks longer than 5 mm, but not bridging the tops of mucosal folds.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_60_16335=[""].join("\n");
var outline_f15_60_16335=null;
